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Abstract
A Novel Computational System for Identication
of Biological Processes from Multi-dimensional
High-throughput Genomic Data
Julian Marshall Dymacek
Identifying potential toxicity signaling pathways could guide future animal studies
and support human risk assessment and intervention eorts. This thesis describes a
novel computational approach for identifying biological processes and pathways that
are signicantly associated with a disease pathology from time series, dose response,
gene expression data.
Our system employs a novel constrained non-negative matrix factorization algo-
rithm and Monte Carlo Markov chain simulation to identify underlying patterns in
mRNA gene expression data. Quantitative pathology can be used as a pattern con-
straint. The found patterns can be thought of as functions that inuence a gene's
expression. Using a database of curated gene sets, we can identify biological processes
that are signicantly related to a pathology.
We also developed a computational model for integrating miRNA with mRNA
time series microarray data along with disease pathology. The dynamic temporal
regulatory eects of miRNA are not well known and a single miRNA may regu-
late many mRNA. The integrated analysis includes identifying both mRNA and
miRNA that are signicantly similar to the quantitative pathology. Potential reg-
ulatory miRNA/mRNA target pairs are then identied through databases of both
predicted and validated pairs. Finally, potential target pairs are ltered, keeping
only pairs that demonstrate regulatory eects in the expression data.
Multi-walled carbon nanotubes (MWCNT) are known for their transient inam-
matory and progressive brotic pulmonary eects; however, the mechanisms under-
lying these pathologies are unknown. In this thesis, we used time series microarray
data of global lung mRNA and miRNA expression isolated from 160 C57BL/6J mice
exposed by pharyngeal aspiration to vehicle or 10, 20, 40, or 80 µg MWCNT at 1, 7,
28, or 56 days post-exposure. Quantitative pathology patterns of MWCNT-induced
inammation (bronchoalveolar lavage score) and brosis (Sirius Red staining, quan-
titative morphometric analysis) were obtained from separate studies.
Understanding the regulatory networks between mRNA and miRNA in dierent
stages would be benecial for understanding the complex path of disease develop-
ment. These identied genes and pathways may be useful for determining biomarkers
of MWCNT-induced lung inammation and brosis for early detection of disease.
Our computational approach detects biologically relevant processes with and without
pathology information. The identied signicant processes and genes are supported
by evidence in the literature and with biological validation.
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Chapter 1
Introduction
Due to limited time and money, biological research has traditionally utilized a com-
partmental approach, focusing on a few targeted genes. These genes may have been
identied from literature, previous experience, or a hypothesis. As genome-wide
analysis has matured, data can be collected from tens of thousands of genes simulta-
neously. This makes identifying genes and biological functions for closer study akin
to nding a needle in a haystack. These identication problems are well suited for
computational approaches and require the application of computer algorithms.
Nanotechnology is an emerging discipline in both industrial and medical elds.
While various nanoparticles have been incorporated into diverse applications, the use
of multi-walled carbon nanotubes (MWCNT) for both industrial and medical pur-
poses is a quickly growing trend. The high surface area/mass and low density of
MWCNT makes them easily aerosolized, thus a potential inhalation hazard during
synthesis, product use and disposal. MWCNT have been widely used for various
industrial applications [92] and exposure has been found to cause rapid onset lung
inammation, brosis and toxicity in treated mice [96, 83]. However, molecular mech-
anisms underlying MWCNT-induced pathogenesis are unknown.
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Identifying biologically relevant processes and functions from time series dose-
response toxicogenomics data is important to reveal toxicity mechanisms and assist
in mechanistic studies by nding signicantly changing genes [1, 52]. While microar-
ray data is noisy and protein levels do not necessarily correspond to mRNA gene
expression levels [47], our system nds novel hypotheses about involvement of dis-
eases, processes, and functions from time series dose response microarray data.
Our system for identifying relevant pathways from time series microarray data
includes several features. First, an analysis should be able to incorporate prior bio-
logical knowledge such as known pathways and relationships between genes. Second,
the system should be able generate hypotheses about potential gene interactions.
Finally, the system should be able to incorporate phenotypical data.
Analyzing time series microarray expression is a dicult task, as many time series
experiments have few time points and are usually noisy [10]. Temporal information
available from time series data is useful for discovering functional mechanisms and
causal relationships. Many techniques have been developed to analyze time series
microarray data [5, 74, 1]. Likewise, microarray data from multiple doses may reveal
potential changes in toxicity and functional mechanisms.
Previously, benchmark dose (BMD)[39] methods have been used to identify a dose
range for response in toxicity tests. By combining BMD with both Gene Ontology
annotations and mRNA expression data, dose range estimates for the response of a bi-
ological processes can be found [119, 120, 121] Dierent models can be used, including
power, linear, second degree polynomial, and third degree polynomial; with the best
t model being used to calculate the safe dose range. For a given biological process
the response was calculated as the median BMD of the genes in the process. Addi-
tional parametric dose response models could be used including Gaussian, quadratic,
and sigmoid [16, 70]. None of these studies included the use of histopathological data.
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Clustering has widely been used for microarray analysis and many techniques
have been tried [5, 4]. Clustering techniques group coexpressed genes based on a
distance metric. Traditional distance based clustering methods can be extended by
creating new metrics that include biological function information [57] and can use
gene annotations [114] from the Gene Ontology annotation tree. However, genes are
still placed into a single coexpression group even though the gene's expression might
be inuenced by multiple processes.
Non-negative matrix factorization(NMF) is a technique developed by Lee and Se-
ung [71] that identies underlying basis patterns used to reconstruct the original data.
NMF has previously been used in microarray analysis [28], however prior information
has not been used in generating the patterns. Like NMF, Bayesian Decomposition
(BD) [88] attempts to nd patterns and coecients that can reconstruct the original
data. However, BD allows for prior biological information to be encoded and inuence
the patterns found. BD has also been used to identify potentially activated pathways
in drug treated time-series microarray data [90] but is not computationally ecient
on the genome wide scale.
While dynamic temporal regulatory eects of microRNA (miRNA) are not well
known, a single miRNA helps regulate many mRNA and therefore act on a multitude
of proteins [8, 78]. The expression of over half of the genes in the human genome
may be regulated by miRNA [41]. Compared to mRNA, miRNA are more stable
and can be isolated from a wide variety of clinical samples while still being measured
by microarray analysis and real-time PCR. These properties make miRNA useful as
potential biomarkers [86].
Unfortunately, miRNA analysis is relatively new and curated annotation databases
are still being created. Integration of well studied mRNA and regulatory miRNA pro-
vide a powerful analysis technique. Traditional integrated methods such as negative
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correlation or simple up- or down-regulation may produce more potential target pairs
especially when using predicted miRNA/mRNA pairs [19, 32, 60, 128]. Unfortunately,
these additional pairs may have no relevance to the known disease pathology. Addi-
tionally, negative correlation rewards pairs that are consistently in opposite directions.
The complex relationship between miRNA and mRNA is not well understood. A sin-
gle miRNA may regulate many mRNA and not consistently negatively correlate with
any single mRNA. An integrated system should allow for miRNA/mRNA pairs that
demonstrate a negative relationship over a subset of the time points.
When dealing with exposure, response time is an important factor. Previously,
non-negative matrix factorization algorithms have been applied to integrated analy-
sis [139, 140] but did not include quantitative pathology data or focus on time series
data. Some new systems are being developed to identify regulator networks from
time series data [102]. These techniques do not focus on analyzing a specic pathol-
ogy. Pathologies, such as exposure response, suggest that miRNA levels should be
consistently changing with the pathology especially if regulating a consistent mRNA
response. Our integrated method allows both divergence between miRNA/mRNA at
individual time points and consistence with the pathology.
This document is organized as follows: Chapter 2 is a discussion of related work
on identifying gene sets from time-series dose-response microarray data; Chapter 3
describes our methodology, the MEGPath system, and results from the application of
our system on mRNA data; Chapter 4 includes an extension of the MEGPath system
for integrating time series dose response miRNA with mRNA; Chapter 5 a description
of in vitro validation and an Ingenuity Pathway Analysis evaluation of the integrated
analysis; nally, Chapter 6 discusses the contributions of our research and potential
future works.
4
Chapter 2
Related Work
Microarrays are a standard technique for measuring genome wide expression values.
Many microarray experiments involve a static snapshot of the genome for a specic
condition with multiple conditions being compared such as a normal sample versus
a cancer sample. Time series experiments involve static samples at various intervals.
These intervals help analyze the temporal process of gene regulation [10] and reveal
underlying functional mechanisms. Various techniques have been used to analyze
time series microarray data [74, 1].
A system for identifying relevant pathways from time series dose response microar-
ray data needs to include several features. First, the analysis system should be able
to incorporate prior biological knowledge linking genes to their functions. Second, the
system should allow genes to be inuenced by multiple underlying functions. Finally,
the system should be able to incorporate phenotypical or pathological data.
This chapter provides a review of the methods and tools related to our study.
An overview of methods for identifying functions and processes is in Section 2.1.
Section 2.2 discusses distance-based clustering methods. A few additional techniques
are discussed in Section 2.3 . A discussion of matrix decomposition methods is in
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Section 2.4. Finally, Section 2.5 gives a summary of the chapter.
2.1 Pathway Analysis
Identifying the biological processes and functions related to a set of genes requires
semantic information linking genes to their functions. This semantic information is
often in the form of gene annotations. There are several databases of gene annota-
tions including the Gene Ontology (GO) project [6], the Kyoto Encyclopedia of Genes
and Genomes (KEGG) [64], and the Reactome project [25]. The Molecular Signa-
tures Database (MSigDB) [76] contains curated sets of genes designed specically for
enrichment analysis and includes large portions of other databases including KEGG,
GO, and Reactome.
Techniques for taking a set of genes and identifying signicant annotations are
called enrichment analysis techniques. Huang [58] surveyed 68 enrichment analysis
techniques and identied three general classes: singular enrichment analysis, modu-
lar enrichment analysis, and gene set enrichment analysis. Khatri [66] uses slightly
dierent nomenclature but identies similar classes.
The class of singular enrichment techniques identies signicant genes and then
the enriched annotation terms. GoMiner [138] is an example of this technique. Genes
with signicantly changing expression are identied, usually using p < 0:05 and a
fold change greater than 1:5. Each annotation term is then checked for signicance
using Fisher's exact test by comparing the number of signicant genes involved with
the annotation term versus the number of signicant genes in the genome. These
techniques often lead to an over abundance of signicant genes and terms.
Modular enrichment techniques incorporate singular enrichment analysis tech-
niques while utilizing the relationships between annotation terms. An example of a
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modular enrichment technique is the DAVID algorithm [59]. DAVID works by creat-
ing pairwise kappa statistics of gene-gene and term-term interactions. Cohen's kappa
statistic is a measure for agreement of categorical terms while adjusting for chance.
The categorical annotation terms come from the DAVID Knowledgebase [105] which
provides an integration of various gene annotation databases while also handling var-
ious gene IDs.
Gene Set Enrichment Analysis (GSEA) [111] is a technique for identifying biolog-
ical functions and pathways from both expression data and annotation data. GSEA
works on the expression data for the genome and does not require identifying a set of
interesting genes instead identifying a subset of genes which are over represented in
a process or function. Through label permutation GSEA can identify processes that
signicantly dier over conditions. The standard GSEA algorithm is not well suited
for time series data as the time points must be treated as separate conditions.
2.2 Point-Wise Distance-Based Clustering
Clustering has been widely used for microarray analysis for many years with multiple
techniques having been tried [5, 4]. Point-wise distance-based clustering methods are
used to describe the distance between two genes. Thresholds can be set to group
similar genes into clusters. Many dierent distance metrics have been used, some of
which are listed in Table 2.1. Some distance methods, such as linear correlation [95],
do not work particularly well for time-series microarray data.
Once a distance metric has been decided upon, a clustering algorithm must be
used. The traditional clustering algorithm that has been used for analyzing microar-
ray data is k-means analysis [115]. In k-means, genes are partitioned into k clusters
with each gene belonging to the cluster with the closest mean. Lloyd's algorithm [80]
7
Table 2.1: Point-wise distance metrics. Let E be a matrix where E(i; t) is the expres-
sion value of gene i at time point t. Let there be Ng total genes and Nt total time
points.
L1-norm dij =
PNt
t=1 jE(i; t)  E(j; t)j
L2-norm dij =
qPNt
t=1(E(i; t)  E(j; t))2
Mahalanoblis d2ij = (Ei   Ej)t
P 1(Ei   Ej)
Correlation dij = 1  rij
rij =
PNt
t=1(E(i;t)  E(i))((E(j;t)  E(j))pPNt
t=1(E(i;t)  E(i))2
PNt
t=1(E(j;t)  E(j))2
is the standard iterative approach for implementation. In Lloyd's algorithm, genes are
iteratively assigned to the closest cluster and then the cluster means are recalculated.
A related algorithm is the k-median algorithm where a gene is assigned to the cluster
with the closest median. Extensions to k-means have been explored, such as incorpo-
rating the temporal dimension of time-series data [110]. Point-wise techniques work
with time-series data but do not allow genes to be inuenced by multiple underlying
functions.
2.2.1 Self-organizing Maps
Another clustering algorithm that has been used is called self-organizing maps (SOMs)
[113]. A SOM is a set of interconnected nodes and a distance function on the nodes.
The map nodes are initially placed at random, and then are iteratively adjusted.
Genes are added to the SOM in a random order, with the distance between each gene
and each map node being calculated. Then, the closest map node N is moved the
most towards the gene. Other nodes are moved towards the gene based on the map
distance to N . Recently SOMs have been applied to time series microarray data [17].
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procedure CAST
repeat
Choose a gene not in a cluster and assign it to a cluster C
repeat
add to C unassigned genes
remove and genes
until C has converged
until All genes are assigned to a cluster
end procedure
procedure Partitioning Around Medoids
assign each gene to the closest medoids
for all medoid m do
for all data point o do
swap m and o and compute the total
end for
end for
end procedure
procedure k-means
repeat
for all gene do
associate gene with a cluster
end for
for all cluster do
calculate the new centroid of the cluster
end for
until Convergence
end procedure
Figure 2.1: Clustering algorithms
Neither, annotation information or pathology constraints were used.
2.2.2 Biclustering
Biclustering [20] aims to cluster not only the rows (genes) but also the columns
(conditions) of the microarray expression matrix. Biclustering algorithms typically
work iteratively in two stages: a deletion stage and an addition stage. The deletion
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stage removes rows or columns that do not decrease a tness function. After deletion,
previously excluded columns and rows may now lower the tness function. After a
cluster is found, the included conditions are replaced with random data. The cc-
Biclustering algorithm [22] performs biclustering on genes divided by groups instead
of columns. A group might consist of biological replicates or conditions on a given
dose. In general biclustering is NP-hard [81].
One issue with traditional biclustering is that clusters are subsets of the data
and potential temporal eects may be lost. For time-series data, restrictions could
be made to keep contiguous columns [82]. However, expression values are often dis-
cretized into fDownRegulated, NoChange, and UpRegulatedg, however pathology
constraints would be dicult to add.
2.2.3 Fuzzy C-means
Fuzzy c-means clustering [27] is a clustering algorithm where each gene has a degree of
belonging to a cluster. The centroid of a cluster is the average of all genes weighted
by the gene's degree of belonging to that cluster. The degree of belonging allows
genes to belong to multiple co-expression groups, dened by weights. Similar to k-
means clustering, the initial cluster assignments strongly inuence the nal clusters.
Prior biological knowledge can be incorporated [114] by deriving initial assignments
from the Gene Ontology annotation tree. Additionally, the annotation information
is utilized in distance calculation. These techniques allow for genes to be associated
with multiple functions but pathology constraints could be dicult to incorporate.
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2.2.4 Extensions to Distance Methods
Distance based clustering methods can be extended by creating new distance metrics
based on biological function information. A shrinking distance metric is used by
Huang [57] where a parameter r allows for distances to shrink if two genes share
a biological annotation. The r parameter can range between 0 and 1 with only
annotation information being used to no annotation information being used. As with
the number of clusters, a value for r must be tuned to best describe the data.
The SICAGO system [65] utilizes a semantic distance between gene annotations
in the GO project. The semantic distance measures used are based on how much
information the genes share in common. Multiple information content theory metrics
are included with the nal distance incorporating the euclidean distance between
expression. Unfortunately, SICAGO has no way of including known pathological
information.
2.3 Additional Techniques
Additional techniques such as EPIG [23] and ASTRO [116] have been developed for
nding patterns and co-expressed genes.
The EPIG[23] algorithm uses local clusters to help identify patterns for clustering.
All gene proles are initially considered as patterns. A pair-wise correlation is per-
formed amongst all proles, with highly correlated proles being grouped together.
All groups with fewer than six proles are eliminated from consideration. Proles
are again ltered by a signal to noise ratio. Finally, patterns are formed from the
averages of the proles in the groups still remaining. The EPIG system eliminates
the random behavior of many clustering algorithms and nds patterns which correlate
closely with the data. The use of correlation limits a gene's ability to be inuenced
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by multiple functions.
ASTRO [116] is specically designed to analyze time series expression data with
limited time points. The algorithm converts the gene expression matrix to a rank
matrix. A gene's expression is transformed from lowest expression to highest by
ranks:
f5; 15; 10; 20g ) f1; 3; 2; 4gf0; 7; 6; 20g ) f1; 3; 2; 4g
The reduction of information enables ASTRO to have O(nm) complexity were n is
the number of genes and m is the number of samples. There is a loss of information
and rankings lose information about relative dierences between genes.
2.3.1 Model-based Clustering Methods
Model-based clustering methods dier from distance based methods. Model clustering
is not performed on the similarity of gene expression but how closely the genes match
underlying model functions. The model functions can be based on previously known
distributions or prior biological information. Individual clusters of genes are assumed
to match a unique underlying function [93, 46]. Model-based methods are easily
extended to time-series data and are more robust in dealing with noisy data; however,
they are limited to predetermined functions.
Hidden Markov models(HMM) have also been used to analyze time series mi-
croarray data. Unlike traditional clustering techniques, HMMs can be used to cluster
genes [101] while including temporal information. HMMs can be described with the
following parameters: the states Si, i the probability of starting in state Si, aij is
the transition probability from state Si to Sj, and bi(!) is the emission probability
density of a symbol ! 2  in state Si. To cluster the genes, k HMMs are found that
maximize the likelihood. In order to nd the parameters, an iterative algorithm can
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be used where each gene is assigned to a HMM and then the parameters of each HMM
are re-estimated using the genes assigned to it. Genes are limited to being described
by only one function.
2.4 Matrix Decomposition Methods
2.4.1 Principal Component Analysis
Principal component analysis (PCA) is a well known data analysis technique and
has been applied to gene expression data [33] and to time-series microarray data as
well [136]. Given that X is a gene expression matrix, PCA nds the eigenvalues
and eigenvectors of the covariance matrix. The covariance of X is 1
n
XX> and the
following decomposition is possible [106] with D being a diagonal matrix andW being
the eigenvectors of X as columns.
XXT = WDW T
These eigenvectors form a set of orthonormal basis vectors representing underlying
functions in the original data. By using only the k eigenvectors with largest eigenval-
ues, clustering can be performed.
Singular value decomposition (SVD) is a standard solution technique for PCA and
has also been used in microarray analysis [2]. SVD works by factoring the original
expression matrix X into three component matrices:
X = UV >
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The relationship between SVD and PCA can be seen as follows:
XXT = (UV T )(UV T )
T
= ([U ]V T )(V UT )
= [U ][][I][][U ]T
= U2UT
Implementations for SVD are included in many numerical packages including R, Mat-
lab, and Numerical Recipes.
PCA and SVD remain standard techniques and identify underlying basis vectors
without requiring additional parameters to tune. The basis vectors are required to
be orthonormal, making pattern constraints impossible to add. There is also no way
to steer the solution through prior domain knowledge.
2.4.2 Independent Component Analysis
Independent component analysis (ICA) is another technique that has been applied
to time-series microarray data. Unlike PCA, the goal of ICA is to nd a set of
components which are as statistically independent of one another as possible [69, 33].
In signal processing, ICA has been used for blind source separation [63], the problem
of identifyingM sound signals fromN microphones. Many biological signal processing
problems have been cast as blind source separation including processing EEGs[126].
ICA has been applied to microarray data[42, 77, 72]. Unlike PCA the goal is
to minimize the amount of mutual information [69], meaning that ICA nds func-
tions that are as dierent as possible not functions that reconstruct the data. This
constraint makes it dicult to incorporate pathological information or prior domain
knowledge.
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2.4.3 Network Component Analysis
Network component analysis (NCA) [75, 123] is a technique for identifying the bipar-
tite connectivity between regulatory signals and output data. The network derived by
NCA for microarray data, relates transcriptional factor activity (regulatory signals)
to gene expression (output data). The relationship can be dened by the decompo-
sition of a gene expression matrix G, consisting of m genes and n samples for each
gene.
Gmn = CSmp  TFpn
The connectivity matrix, CS, contains the strength of each edge. The matrix TF
contains the regulatory nodes of the network. There are p transcriptional factor
activities. NCA requires three additional constraints:
1. CS has full column rank
2. Each column of CS has at least p  1 zero values
3. TF must have full row rank
These constraints mean that G can be uniquely (up to a scaling factor) decomposed.
The second constraint allows for a regulatory node and its related output nodes to
be removed while still maintaining full column rank for CS.
2.4.4 Non-negative Matrix Factorization
Non-negative matrix factorization(NMF) is a technique developed by Lee and Seung
[71] for use in facial recognition and text mining. NMF attempts to generate a set
of basis vectors H and corresponding coecients W that can be used to reconstruct
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the original data. Given that X is the original gene expression:
[X]nm  [W ]nk  [H]km
There are n genes and m samples (time points). The variable k corresponds to the
number of basis vectors and is usually set to the m   1. If k = m then H becomes
the trivial solution of the mm identity matrix.
NMF algorithms impose the additional constraint that each entry in W , H, and
V must be non-negative. This constraint creates an additive nature to the basis
vectors and allows for intuitive functional meanings. Techniques such as PCA also
nd basis vectors, but allow negative values. Without the non-negative constraint the
linear combinations of basis vectors in PCA can have complexities generated through
cancellations making functional interpretation dicult. Unlike PCA, the basis vectors
in NMF are not required to be orthonormal nor are they required to independent as
in ICA.
NMF has been explored in microarray analysis, for a review of techniques see [28].
Algorithms that generate sparse basis vectors have also been explored [67] as sparse
basis vectors identify specic functions particularly well.
A weakness of the NMF algorithms is the exclusion of prior information such as
pathology data. The iterative techniques of most methods make additional constraint
steps lead to numerical instability or loss of the central non-negative constraint. A
limited amount of prior information (cell type) can be incorporated by identifying
select marker genes and forcing their reconstruction to exactly one basis vector [45].
Similar techniques would be dicult to work for constraints on the basis vectors.
16
2.4.5 Bayesian Decomposition
A diculty with traditional NMF techniques is that prior information cannot be used
to help generate the patterns. Like NMF, Bayesian Decomposition (BD) [88] attempts
to nd patterns and coecients that can reconstruct the original data. However, BD
allows for prior biological information to be encoded and inuence the patterns found.
BD works as a Monte Carlo Markov Chain, which explores the state space of possible
patterns and coecients by updating probability density functions. By using Bayes'
formula prior information can be used to guide the exploration. BD has also been
used to identify potentially activated pathways in drug treated time-series microarray
data [90]. Unfortunately, BD has proven to be computationally inecient in general
practice and provides no way of constraining an entire pattern to match pathology.
2.5 Summary
In this chapter we reviewed current methods and tools for analyzing time series, dose
response microarray data. We have identied some requirements for our method-
ology and have identied that no existing system currently implements all of our
requirements.
We propose a computational system, presented in Chapter 3, for identifying rel-
evant biological functions and processes from time series, dose response microarray
data. Our system incorporates prior biological knowledge linking genes to their func-
tions, phenotypical or pathological data, and allows genes to be related to multiple
functions.
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Chapter 3
The MEGPath System
In this chapter, we present our methodology for analyzing time series dose response
high throughput data. Our system for identifying relevant pathways from time series
microarray data includes several features: rst, the ability to incorporate prior biolog-
ical knowledge such as known pathways and relationships between genes; second, the
ability to generate hypotheses about potential gene interactions; nally, the ability
to incorporate phenotypical data. As discussed in Chapter 2, there is a need for a
system capable of combining all of these elements.
Identifying biologically relevant processes and functions from time series dose-
response toxicogenomics data is important to reveal toxicity mechanisms and assist
in mechanistic studies by nding signicantly changing genes [1, 52]. While microar-
ray data is noisy and protein levels do not necessarily correspond to mRNA gene
expression levels [47], our system nds novel hypotheses about involvement of dis-
eases, processes, and functions from time series, dose response microarray data. An
overview of our system can be seen in Figure 3.1.
Clustering has widely been used for microarray analysis and many techniques
have been tried [5, 4]. Clustering techniques group co-expressed genes based on a
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distance metric. Traditional distance based clustering methods can be extended by
creating new metrics which include biological function information [57] and can use
gene annotations [114] from the Gene Ontology annotation tree. However, clustered
genes are still placed into a single co-expression group even though a gene's expression
might be inuenced by multiple processes.
Non-negative matrix factorization(NMF) is a technique developed by Lee and
Seung [71] that identies underlying basis patterns used to reconstruct the original
data. NMF has previously been used in microarray analysis [28] but prior information
has not been used in generating the patterns. Like NMF, Bayesian Decomposition
(BD) [88] attempts to nd patterns and coecients which can reconstruct the original
data. However, BD allows for prior biological information to be encoded and inuence
the patterns found. BD has also been used to identify potentially activated pathways
in drug treated time-series microarray data [90] but is not computationally ecient
on the genome wide scale.
The MEGPath system identies a set of non-negative patterns which represent
underlying biological functions. The patterns are used to relate each gene to the
underlying functions that direct its gene expression. The MEGPath system allows
for constraints to be added on to the patterns such as representing a known pathology.
This chapter describes the MEGPath system and its application to mRNA data.
Section 3.1 is a discussion of data sets and describes the four stages of our method-
ology. Section 3.2 is an algorithmic complexity analysis of the dierent parts of
the system. System verication is covered in Section 3.3. Results of our system on
mRNA data are described in Section 3.4 including the visualization and results with
and without pathological information. Finally, Section 3.5 gives a discussion of the
methodology and ndings.
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Figure 3.1: Overview of the four steps in the algorithm. Step 1: Identify signicantly
changing genes using SAM and linear model. Step 2: Find patterns and coecients to
reconstruct the gene expression data. Step 3: Find coecients for the entire genome.
Step 4: Using the patterns, coecients, and pathways, we can identify signicant
pathways. The results can be veried using both Ingenuity Pathway Analysis and
biological testing.
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3.1 Materials and Methods
Our system, MEGPath, as shown in Figure 3.1, is divided into four main components:
the Gene Identication component, the Pattern Finding component, the Coecient
Expander component, and nally the Functional Process Evaluation component. The
MEGPath system is capable of generating novel hypotheses about genes by grouping
genes to system identied patterns. In addition, the MEGPath system allows for
constraints, such as a quantitative pathological data, to be added as prior informa-
tion. The additive nature of the system enables genes to be associated with multiple
patterns while maintaining understandable interactions. Finally, the Functional Pro-
cess Evaluation step allows prior biological information, such as gene interactions and
annotations, to be related to the expression data and tested for signicance.
3.1.1 Data Sets
The data sets consisted of dose-dependent time series mRNA microarray expression
data as well as quantitative pathology scores from an aspiration experiment. In total
480 mice were randomized into three groups: genome-wide mRNA expression, lung
pathology scores, and brosis pathology scores. Scores were found for 1, 7, 28, and
56 days post-exposure with the mice exposed to 0, 10, 20, 40, or 80µg of MWCNT.
Total RNA was extracted from the mice at each dose condition. Agilent Mouse
Whole Genome Arrays were used for expression proling. In total, our genome con-
sisted of 41,059 probes and the data has been deposited to the NCBI Gene Expression
Omnibus (GEO) repository using accession number GSE29042. The microarray data
were log-transformed for analysis. The expression of each gene at each treatment
condition can be visualized through a web-interface.1
1(http://www.mwcnttranscriptome.org)
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In addition to mRNA expression data, 160 mice were used for inammation scores.
Inammation scores (BAL polymorphonuclear leukocytes) were derived from the anal-
ysis of BAL uid taken from the MWCNT exposed mice [96]. In total 4mL of lavage
uid was collected and BAL cells were isolated by centrifugation. BAL cell counts
were obtained using a Coulter Multisizer 3.
An additional 160 MWCNT exposed mice were used for brosis scores. Scores
were found using morphometric analysis of Sirius Red staining for connective tissue
[83]. Paran sections of the left lung were sliced and then rehydrated. After Sirius
Red staining, the average thickness of connective tissue bers in the alveolar region
were obtained through quantitative morphometric methods.
3.1.2 Gene Identication
For each dose and time point, a set of dierentially expressed genes were identied
by performing a two-class unpaired Signicance Analysis of Microarrays (SAM) [125]
between the treated samples and the zero dose samples from the corresponding time
point, using the Bioconductor package. A threshold delta value was chosen to produce
a false discovery rate of 1% using the ndDelta function from the same package. The
list of signicant probes was subsequently ltered, keeping probes that were at least
1.5 fold up- or down-regulated. Fold changes were computed from the data before
imputation of missing values.
Additionally, a linear model was t to the data, modeling the log expression of each
gene as a function of time, dose, and the interaction of time with dose. We moderated
the t-statistic associated with the dose and interaction parameters following the SAM
algorithm and set a threshold to control for a false discovery rate of 0:1%. This
generated a list of genes with expression values that were signicantly dependent on
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dose and a list of genes with expression values that were signicantly dependent on
dose in a time-dependent fashion.
3.1.3 Pattern Finding
The Pattern Finding algorithm (Algorithm 3.2) is a non-negative matrix factorization
algorithm. Our algorithm identies a set of non-orthogonal basis patterns (vectors)
which can be linearly combined to reconstruct the original gene expression data. In
addition to the patterns, the algorithm nds coecients relating each gene to each
pattern. The most important feature of the Pattern Finding algorithm is the ability
for genes to be associated with multiple patterns.
Let D be the original data matrix, we wish to nd the matrices P and C such
that, D = C  P . Gene expressions are normalized to be in the range [0; 1) so that D
contains the normalized fold change values.
The matrix P consists of the patterns that are used as the basis vectors. Each row
contains one pattern as expressed across the experiment conditions. For example, a
pattern is made of an expression value at each time point or an expression value for
each dose across a time point. Patterns are the average response of similar genes and
the patterns in P provide biologically relevant information.
The matrix C is the coecient matrix, consisting of one row for each gene and one
column for each pattern. The coecients represent how strongly a gene is associated
with a particular pattern.
The Pattern Finding algorithm works as a Monte Carlo Markov Chain. Each
entry in the coecient and pattern matrices has an associated probability density
function (PDF). During each Monte Carlo Markov Chain step an entry is altered
and the overall error is computed. If the change reduces the overall error, then the
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procedure FindPatterns
e TotalError(D;C; P )
i 0
while e > 0 and i < MaxIterations do
for all v 2 P and C do
v  Random(v's PDF )
e1  TotalError(D;C; P )
if e >= e1 then
add r to the PDF
end if
e e1
i i+ 1
end for
end while
end procedure
Figure 3.2: The Pattern Finding algorithm.
PDF associated with the entry is updated. The pseudocode for the Pattern Finding
algorithm is listed in Figure 3.2.
Prior information can be used to constrain a search. The constraints are formed
by modifying an entry's PDF. The PDF of an entry could be constrained to always
return the same value or pathological data could be encoded as a pattern constraint.
For a pathology constraint, it is important that the pattern entries maintain their
relative distances but be allowed to shift up or down as a group. This shifting can be
accomplished with a single variable and an associated PDF.
After generating the PDFs, the Pattern Finding algorithm uses simulated an-
nealing to minimize the overall error, using a standard annealing function [97]. The
simulated annealing process utilizes each entrys's PDF and works in a similar manner
to the original Monte Carlo Markov Chain.
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3.1.4 Coecient Expander
Coecients are found using the Pattern Finding step. By using the Gene Identica-
tion step to identify signicantly changing genes, not all genes will have coecients.
Genome-wide coecients are insured by using the Coecient Expander algorithm.
The Coecient Expander step attempts, through the use of simulated annealing, to
nd optimal coecients for each gene in the genome. Each gene's coecients should,
when combined with the patterns, minimize the distance between the calculated ex-
pression and the actual expression.
3.1.5 Functional Pathway Evaluation
The nal step is to calculate the Functional Process Evaluation (FPE) score for a given
set of genes. The FPE score is based on the score from Gene Set Enrichment Analysis
[111]. Each gene's coecients are normalized to obtain the relative importance of a
pattern to the gene. Genes that are not common to both the pathway and genome
are ignored and not used in computing the score. If a gene has multiple probes, the
probe with least reconstruction error is chosen.
The FPE score ranges from -1 to 1 with the scores being computed for each
pattern. Scores are calculated by rst sorting the genome by the pattern coecient.
After sorting, the genes with the highest coecients for a pattern will be at the
beginning. Scores are computed by starting at the highest ranking genes and either
adding a value (for genes in the set) or subtracting a value (for genes not in the set).
The highest score generated is used as the FPE score. Higher FPE scores correspond
to sets of genes which are over-represented at the beginning. Leading sets are the
genes that are used to generate the FPE score and are the genes considered most
closely related to a pattern for the pathway. An overview of the FPE algorithm is
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phit; pmiss; score 0
for all g 2 G do
if g 2 P then
phit  phit + C(g)=S
else
pmiss  pmiss + 1=(Ng  Np)
end if
if score < phit   pmiss then
score phit   pmiss
end if
end for
return score
Figure 3.3: The FPE score is based on the positive score from Gene Set Enrichment
Analysis. Let the genome G contain Ng genes and P be gene set of Np genes. Also
let S be the sum of the coecients of the genes in P and C(g) be the coecient of a
gene g.
described in Figure 3.3.
A pathway's p-value is found by comparing its FPE score to the score of thou-
sands of randomly generated gene sets of the same length and counting the number of
random sets with higher scores. After p-values have been calculated for all the path-
ways, the Benjamini-Hochberg [11] method is used to adjust for multiple hypothesis
testing. Gene sets with a p-value less than 0.05 are considered signicant.
3.2 Algorithm Analysis
A complexity analysis of the MEGPath system involves looking at three components:
Pattern Finding, Coecient Expander, and the Functional Pathway Evaluation. The
Gene Identication step, a single preprocess step utilizing the standard SAM algo-
rithm, is not analyzed here.
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3.2.1 Pattern Finding
The Pattern Finding algorithm tries to reduce the error dierence between the original
data D and the product of the the coecient matrix C and pattern matrix P . Let n
be the number of genes, m be the number of conditions, and m   1 be the number
of patterns. A basic solution for nding the error involves a matrix multiplication,
an entry by entry subtraction, and a sum of all the entries. A standard worst case
complexity analysis of matrix multiplication involves counting the number of scalar
multiplications [24]. The basic solution would have n m  (m   1) multiplications
for each change to the P or C matrices. In total, there would be n m  (m   1) 
(n  (m  1) +m  (m  1)) multiplications, O(n2 m3).
Now, we will consider our algorithm that limits the multiplications for each entry's
update. First, note that when changing a gene's coecient, only one row will change
in the product of C and P . This one row will contain m values and will require
m  (m  1) multiplications. When changing an entry in P an entire column will be
changed. The column change requires n  (m   1) multiplications. The optimized
error procedure takes n m  (m  1)  (1 + (m  1)) multiplications, O(n m3). Our
data, n = 2; 996 and m = 4, is similar to most gene data where the number of genes
is much larger than the number of conditions. The entry subtraction and sum can be
reduced by caching entry error values and updating them during the multiplication
process. The total number of iterations can vary but is independent of the number
of genes or conditions.
3.2.2 Coecient Expander
The Coecient Expander algorithm attempts to nd coecients that minimize the
error in a gene's reconstruction. Unlike the Pattern Finding algorithm, no changes
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are needed to the pattern entries. The m   1 coecients corresponding to the m
patterns are optimized. Each optimization step requires m  (m  1) multiplications.
The total number of optimizations can vary but is independent of the number of genes
or conditions.
3.2.3 Functional Pathway Evaluation
The Functional Pathway Evaluation algorithm attempts to nd sets of genes signi-
cantly related to a pattern. The algorithm must compute the FPE score for each gene
set and then compute FPE scores for 1,000 randomly generated sets. The FPE score
calculation requires a one time sorting of the genome and then an iteration through
the genome. Each gene is checked for inclusion in the set. If a hashtable is used to
store the set, the algorithm will run in linear time according to the size of the genome.
3.3 Verication of the Algorithm
No \gold standard" data sets exist that incorporate all of the features used by the
MEGPath system. Each of the components were individually evaluated to ensure
that each component worked as intended.
3.3.1 Pattern Finding
The Pattern Finding component was evaluated to ensure that known patterns could
be extracted from a generated data set. Expression values for three, randomly chosen
probes at 40 µg across the four time points were used as the underlying patterns.
These three patterns were then combined using randomly chosen weights to create
3,000 generated test expressions. By comparing the original patterns with the found
28
patterns, we can determine if MEGPath is capable of revealing known underlying
patterns. A test set of 3,000 generated expressions were used with patterns found
from 16 consecutive runs.
To check if patterns were better than random, three randomly selected probes
were chosen as patterns and used for genome wide reconstruction. These probes were
normalized and then the Coecient Expander step was run to compute the total
error. The results of this test suggest that the MEGPath system found patterns that
are better than randomly chosen patterns.
3.3.2 Comparison with other Non-negative Matrix Factor-
ization Algorithms
Since our system utilizes a NMF algorithm we tested our algorithm's ability to iden-
tify data reconstruction patterns against other NMF algorithms. Algorithms were
used from the NMF package for R [44] that is designed for bioinformatics use and
for algorithm comparison. The NMF package includes eight standard algorithms:
Brunet, Frobenius, KL, Lee, Oset, SNMF/l, and SNFM/R. The Lee algorithm is
the original NMF algorithm. The SAM-Set of signicantly changing probes was used
to generate 100 sets of 300 randomly selected genes. Patterns and reconstruction
error were found for each set of randomly selected genes. The pattern nding uti-
lized both the inammation (dose 40) pathology constraint as well as no pathology.
The algorithms were run four times and the average reconstruction error was calcu-
lated. The algorithms were ranked in descending order of reconstruction error with
the largest error being ranked zero and the smallest error being ranked nine. The
Pattern Finding algorithm, both with (p < 0:01) and without (p < 0:01) pathology
information, had average ranks signicantly higher than all other algorithms. As seen
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in Figure 3.4, both the constrained and unconstrained algorithms nished with an
average rank of more than eight.
MEGPath - NMF Reconstruction Error Comparison
Ra
nk
ing
0
1
2
3
4
5
6
7
8
9
10
Method
Co
ns
tra
ine
d
Un
co
ns
tra
ine
d
bru
ne
t
Fro
be
niu
s KL lee
ns
NM
F
off
se
t
sn
mf
/l
sn
mf
/r
MEGPath Average Position
NMF Average Position
Table 3
0.599326221011495 1.02000198058829 0.683056115239192 1.09175051725163 0.860819435776227 0.658740763836119 0 0 0.1 0.14213381090374
* *
Figure 3.4: A comparison of the Pattern Finding algorithm to traditional NMF algo-
rithms by the average reconstruction error. Gene expression for dose 40 µg across the
four days was used to generate 100 sets of 300 genes each. Each algorithm was run
four times on each set with the rankings assigned by descending order of error. The
Pattern Finding algorithm (utilizing both pathology constraints and no constraints)
performed signicantly (p < 0:01; Wilcoxon Signed-Rank Test and Mann-Whitney)
better than all other algorithms.
3.3.3 Functional Process Evaluation
The Functional Process Evaluation algorithm was also evaluated using a mock data
set. First, a \genome" of 2,500 genes was created with 100 of the genes being labeled
as interesting. Coecients were randomly generated using a normal distribution with
the 100 highest coecients being assigned to the interesting genes. A set consisting
of 50 randomly chosen interesting genes was generated and compared to 99 sets of
randomly chosen genes. Only the set consisting of the interesting genes was found to
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be signicant (p < 0:01).
3.4 Results
In many in vivo experiments, disease pathologies may be observed. However, the
underlying molecular mechanisms may not be understood. As seen in Figure 3.1,
the MEGPath system is used in conjunction with dose response, time series mRNA
microarray data and quantitative pathology scores. In total, 480 mice were used to
generate data in an aspiration experiment with scores being found at 1, 7, 28, and 56
days post exposure and eight mice exposed to 0, 10, 20, 40 and 80µg of MWCNT at
each time point. The mice were divided into three groups: 1) genome-wide mRNA
expression proling was performed on 160 mouse lung tissue, 2) BAL inammation
scores found for 160 mice, and 3) morphometric analysis of Sirius red staining for
collagen on 160 mice [83, 96]. These data provided genome-wide expression data as
well as matching quantitative pathology for lung inammation and lung brosis. The
combination of data allows the system to identify both pathways and genes which
may be directly related to the pathology. The MEGPath system consists of four
parts: Gene Identication, Pattern Finding, Coecient Expansion, and Functional
Process Evaluation.
The Gene Identication step was run on the 41,059 mRNA probes and found a
total of 2,996 probes that were signicantly changed. We call this set of signicant
probes the SAM-Set. The Pattern Finding algorithm found patterns from the SAM-
Set. Pattern coecients were then found for each gene in the genome.
The Functional Process Evaluation step was used to identify leading sets. Gene
sets from the MSigDB [111] C2 Canonical Pathways and C5 Gene Ontology databases
were used. The C2 and C5 databases consist of a combined 2,334 curated sets of genes
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corresponding to metabolic and signaling pathways as well as sets derived from the
GO project. These gene sets provide curated information on functional relationships
between genes.
3.4.1 Evaluation of the MEGPath system
To check if the MEGPath system was capable of identifying patterns from expres-
sion data, we generated 3,000 test expressions. All expressions were generated from
a random combination of the same three randomly chosen probes, A 51 P227275,
A 51 P454519, and A 52 P342202. The Pattern Finding algorithm was run 16 con-
secutive times, each time nding three patterns. The identied patterns closely re-
semble the original probes' patterns as seen in Figure 3.5, demonstrating that the
system can identify patterns known to be in the data. In addition, this demonstrates
that the normalization of the gene expression does not aect the ability of the system
to nd relevant patterns.
To compare if the patterns found by the system were better than randomly chosen
patterns, three probes were randomly chosen and used for data reconstruction. This
randomized process was run 100 consecutive times (Figure 3.6), each time with new
probes as patterns. Overall the random patterns produced an average reconstruc-
tion error of 1727.318. However, using patterns found while incorporating the Gene
Identication, Pattern Finding and Coecient Expander steps yielded over eight con-
secutive runs an average reconstruction error of 998.515. The found patterns resulted
in a signicant (p < 0:01) reduction in error over randomly chosen patterns with the
found patterns always performing better than the randomly chosen ones.
To justify using the Gene Identication step, the SAM-set patterns were checked
to see if they reduced the overall error. Patterns were found using the full genome
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Figure 3.5: Patterns were found in mock data generated from three actual probes.
The mock data consisted of 3,000 \genes" which were generated from three randomly
selected probes. Gene expression for dose 40 µg across the four days was used. The
patterns shown are the average of 16 consecutive runs.
and the total reconstruction error was computed. For comparison, patterns were
found using the SAM-Set only and the total error was computed after using the
Coecient Expander step. Eight consecutive trials were performed and, using the
Gene Identication step, always led to lower total error as seen in Table 3.1. Using
an unpaired t-test, the means of the two groups signicantly diered (p < 0:01).
Since the SAM-Set is always a strict subset of the whole genome this means that
using the Gene Identication step reduces pattern nding time while not increasing
reconstruction error.
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Figure 3.6: A comparison of the reconstruction error of both the Pattern Finding
algorithm and randomly chosen probes. Figure A shows the results of 100 consecutive
reconstructions each using randomly chosen probes as the patterns. Figure B shows
the results of eight consecutive runs with patterns identied from the MEGPath
system. The system identied patterns performed signicantly (p < 0:01) better on
average than the randomly chosen probes.
Table 3.1: Comparison of error of reconstruction between patterns found using all
probes and the 2996 probes. Using an unpaired t-test, the two groups were found to
dier signicantly with p < 0:01 .
All Probes 2996 Probes
1170.233 1131.003
1209.015 1032.582
1269.886 1086.619
1298.348 934.891
1170.796 907.779
1138.710 876.944
1182.705 887.915
1195.762 1130.390
3.4.2 Incorporating histopathological data
The MEGPath system can incorporate quantitative pathological data. Pathological
scores of pulmonary inammation data (BAL polymorphonuclear leukocytes) for the
40 µg dose across the time points [96] were used to identify inammation related
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Table 3.2: Selected Pathways found signicant to Pattern 1 in Dose 40 g, using an
constrained search and the C2 database.
Pathway Adjusted p-value
SIGNALING IN IMMUNE SYSTEM 0.0
REGULATION OF INSULIN SECRETION 0.0
SIGNALING IN IMMUNE SYSTEM 0.0
REGULATION OF INSULIN SECRETION 0.0
LYSOSOME 0.0
T CELL RECEPTOR SIGNALING PATHWAY 0.0
ECM RECEPTOR INTERACTION 0.0
PRIMARY IMMUNODEFICIENCY 0.0
G2 PATHWAY 0.0
CELL CYCLE MITOTIC 0.01318
CHEMOKINE SIGNALING PATHWAY 0.01318
G1 S TRANSITION 0.01318
PLATELET ACTIVATION TRIGGERS 0.01318
FMLP PATHWAY 0.01318
INTESTINAL IMMUNE NETWORK FOR IGA PRODUCTION 0.02292
FORMATION OF PLATELET PLUG 0.02726
IL2RB PATHWAY 0.02726
pathways. The leading set of a pathway is the subset of genes that are most closely
related to the pattern. Since genes are allowed in multiple co-expression groups, not
all genes in a pathway's leading set have identical looking expression. However, as
seen in Figure 3.7, the average expression of the leading set closely resembles the
pattern. The pathological pattern was xed as Pattern 1 with the other two patterns
being found automatically by the system. The SAM-Set probes were used in the
Pattern Finding component. In total, 111 gene sets were found to be signicant with
Pattern 1 for 40 µg dose across the time points with a constrained search. Several
signicant pathways are related to cell proliferation, immune response and chemokine,
which are reported to be relevant to inammation in the literature (Table 3.2).
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Figure 3.7: Average of the genes in the leading set of Chemokine Activity from the C5
database (A), Reactome Signaling in Immune System (B) from the C2 database, and
Defense Response from the C5 database. The constrained histopathological patterns
are also shown: day 56 brosis (A), dose 40 µg inammation (BAL polymorphonuclear
leukocytes) (B), and dose 80 µg brosis (C).
In order to identify mechanisms related to brosis, the average thickness of the
alveolar connective tissue [83] was used as a pathological pattern. Patterns were
found for the 80 µg dose across the time points and for day 56 across the doses. As
with the inammation data, Pattern 1 was constrained to the pathological pattern
and was normalized to the range of 0 to 1 and the SAM-Set probes were used to nd
patterns. In total, 69 gene sets were found to be signicant with Pattern 1 for 80 µg
dose across the time points with a constrained search. Likewise, 85 gene sets were
found to be signicant with Pattern 1 for day 56 across the doses using a constrained
search.
Experimental validation was achieved by rst using Ingenuity Pathway Analysis
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to identify, from the leading sets identied by our system, the genes with known
involvement in inammation or brosis. In total, IPA found 67 genes that were
involved with inammation with ccl2 occurring most frequently in leading sets. Ccl2
was selected for in vitro analysis. After treatment with MWCNT, protein levels were
signicantly up-regulated, suggesting that ccl2 responded similarly in vitro as in vivo.
These results suggest that in vitro study may be used for future study of ccl2 and
MWCNT [37].
3.4.3 Without histopathological data
The MEGPath system can nd pathways, functions and genes when using both
pathology data and expression data. Pathogenesis progress is important for toxicity
as aected organs may not be known. We further explored to see if we could identify
potential pathologies using only mRNA expression data. Patterns were found using
the dierent doses across days. As demonstrated in Figure 3.8, the system nds gene
sets whose expression may vary at points but as a group strongly resembles the pat-
tern, genes may be inuenced by multiple functions and not have identical patterns
of expression. All patterns were found using the SAM-Set probes with coecients
expanded to all probes using the Coecient Expander algorithm.
Signicant pathways, Table 3.3, were found to match Pattern 1 for the 40µg dose
across the time points. The average expression of the leading sets resembles the
lung inammation pattern (BAL polymorphonuclear leukocytes) reported by Porter
et al.[96] in the same animal studies. The results show when no pathological data is
provided, our system nds potential pathological patterns and related pathways from
time series gene expression data.
The MEGPath system can also be used to identify patterns using multiple days
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Figure 3.8: (A) The average expression for the leading sets which matched Pattern
1 using an unconstrained search. (B) The average expression of the leading set for
KEGG Primary Immunodeciency with the inammation histopathology (BAL poly-
morphonuclear leukocytes) included for comparison.
Table 3.3: Pathways found signicant to Pattern 1 in dose 40 µg, using an uncon-
strained search and the C2 database.
Pathway Adjusted p-value
KEGG LYSOSOME 0.0
KEGG PRIMARY IMMUNODEFICIENCY 0.04393
REACTOME CLASS A1 RHODOPSIN LIKE RECEPTORS 0.04393
REACTOME GPCR LIGAND BINDING 0.0
REACTOME INTEGRIN CELL SURFACE INTERACTIONS 0.0
REACTOME PEPTIDE LIGAND BINDING RECEPTORS 0.0
and multiple doses. Seven patterns were found from the SAM-Set of probes across
eight conditions, using the 40 µg dose and the 80 µg dose across the time points. Many
of the patterns exhibit strong similarity between the 40 µg dose sections and the 80 µg
dose section (Figure 3.9). The results suggest similar dose response in both the 40 µg
and 80 µg doses and the potential for future experiments not needing the higher dose.
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Figure 3.9: The seven patterns found using an unconstrained search and eight con-
ditions. The SAM-set was used but included the conditions for dose 40µg and dose
80 µg, both across the four time points. The patterns are split into the dose 40 µg
segment and dose 80 µg segment to show similarity.
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3.4.4 ClueGO Visualization
A visualization of the gene relationships in a leading set can be created with the
ClueGo [12] tool. For these gene lists, a functional analysis of only a single cluster
was conducted. The gene cluster list was populated using the model species as Homo
Sapiens and allowing ClueGO to automatically select correct identiers. ClueGO
allows the user to specify the level of detail they wish to acquire from the analysis,
ranging from highly detailed results to a broader more general global setting. In this
analysis, the slider was placed upon the medium setting showing no favor towards
the global or detailed option. The GO biological process was selected as the ontology
of choice using all available codes. The leading sets for the Immune Response path-
way (Figure 3.10) and Response To External Stimulus pathway (Figure 3.11) were
visualized.
3.5 Discussion
Dose response and time series experiments are an important tool for identifying toxi-
city and disease progression. Previous studies have used in vivo and in vitro genome-
wide mRNA expression data to infer toxicity. In addition to microarray data, bench-
mark dose techniques have been combined with Gene Ontology annotations, to iden-
tify biological processes related to toxicity. However, even if quantitative pathology
is observed, the underlying molecular mechanisms may be dicult to reveal.
Our system, Figure 3.1, uses both mRNA expression data and quantitative pathol-
ogy scores to identify signicantly changing pathways and interesting genes. We were
able to identify results that are able to be experimentally validated [37].
The MEGPath system, involving a combination of Gene Identication, Pattern
Finding, Coecient Expansion and Functional Process Evaluation methods, is a com-
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Figure 3.10: The Immune Response leading set as visualized by ClueGO.
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Figure 3.11: The Response to External Stimulus leading set as visualized by ClueGO.
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putationally ecient technique to model dose dependent time series microarray data
on the genome-scale. Our system identies non-parametric patterns capable of re-
constructing both dose dependent and time series microarray data, while also in-
corporating quantitative pathological data and known biological interactions. Genes
are allowed in multiple co-expression groups and so can be signicantly related with
multiple functions and patterns.
However, the MEGPath system is not suited for working with data consisting of
less than three treatment conditions. Also, unlike parametric systems, no information
can be implied from unobserved experimental conditions. While our system suggests
that two doses may behave the same, we can make no claim about unobserved middle
doses. The system also depends on curated gene sets, which depending on granularity,
may be too general.
When no pathological data is available, this system is able to identify potential
pathological phenomena and related pathways. Future experiments can be developed
for testing potential pathologies by observing trends in the identied signicant path-
ways. The MEGPath system has potential applications in areas outside of toxicology
such as chemo response, chemo sensitivity, and pharmacogenomics. For instance, us-
ing mRNA expression data from blood could reveal the eects of unobserved diseases
or organs with potential diseases. Observing patterns across multiple days or doses
could help reduce the number of conditions needed in future experiments. Repetitive
higher doses could be removed, or long durations might be shortened.
3.6 Publications
Some the work described in this chapter has been published in proceedings of the IEEE
International Conference on Bioinformatics and Biomedicine. In addition a journal
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J. Dymacek and N. L. Guo. Systems approach to identifying relevant path-
ways from phenotype information in dose-dependent time series microarray data.
In Proceedings of the 2011 IEEE International Conference on Bioinformatics and
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Chapter 4
Integrated miRNA/mRNA
Analysis
In this chapter we will explore the integration of miRNA with mRNA. The integrated
mRNA and miRNA analysis (Figure 4.1) of time series microarray data will involve
separate processing of both the expression data sets described in Chapter 3. Central
to the analysis is the identication of genes (miRNA and mRNA) that correspond
with the given quantitative pathology. After identifying genes, only genes that are
either predicted or known target pairs will be kept. In addition, for each target
pair there must be gene expression evidence of regulation. In Chapter 5, the results
will be analyzed with Ingenuity Pathway Analysis and pathology involvement will be
validated from the literature.
The dynamic temporal regulatory eects of microRNA are not well known. We
introduce a technique for integrating miRNA and mRNA time series microarray data
with known disease pathology. The integrated analysis includes identifying both
mRNA and miRNA that are signicantly similar to the quantitative pathology. Po-
tential regulatory miRNA/mRNA target pairs are identied through databases of
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both predicted and validated pairs. Finally, potential target pairs are ltered by
examining the second derivatives of the fold changes over time. Our system was
used on genome-wide microarray expression data of mouse lungs (n = 160) following
aspiration of multi-walled carbon nanotubes. This system shows promise of readily
identifying miRNA for further study as potential biomarker use.
The remainder of this chapter is organized as follows. Section 4.1 describes the
methods used to analyze both the mRNA and miRNA data. Results are described in
Section 4.2.
4.1 Methods
The integrated mRNA and miRNA analysis (Figure 4.1) of time series microarray
data involves separate processing of both the expression data sets. Central to the
analysis is the identication of genes (miRNA and mRNA) that correspond with
the given quantitative pathology. After identifying genes, only genes that are either
predicted or known target pairs are kept. In addition, for each target pair there must
be gene expression evidence of regulation.
4.1.1 Non-negative Matrix Factorization
Non-negative matrix factorization [71] (NMF) allows for the identication of underly-
ing patterns in multi-dimensional microarray data. These patterns can be thought of
as biological functions responding to a disease or exposure. By xing, or constraining,
one pattern to a known pathology, we can identify genes that are strongly inuenced
by a function resembling the pathology.
Let D be the original fold change data (either mRNA or miRNA expression data),
containing values at multiple conditions for each probe. The NMF algorithm tries
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Figure 4.1: Flow diagram of an integrated miRNA/mRNA analysis. Both microar-
ray data and pathology data are used in the miRNA and mRNA analysis. Genes
signicant with the pathology are identied and then potential target pairs analyzed.
47
to nd matrices P and C such D = C  P . The pattern matrix, P , consists of
underlying biological functions that can be used to reconstruct the expression data.
The coecient matrix, C, relates each probe to the each pattern. Due to noise, it
is unlikely that an exact solution can be found. The algorithm tries to minimize the
dierence between the original fold change matrix (D) and the reconstructed fold
change (C  P ).
Our NMF algorithm works as a Monte-Carlo Markov Chain, where a probability
density function is associated with each entry in the P and C matrices. To satisfy
the non-negative constraint the fold change data is normalized to the [0  1) domain.
The density functions are updated at each algorithm step and nal entry values are
found using a simulated annealing process.
Unlike traditional NMF algorithms, our algorithm allows constraints to be added.
Constraints are implemented through manipulation of the density functions. A den-
sity function can be shared across multiple entries or constrained to always return
a specic value. Pathology patterns are encoded as a single density function with a
time series pathology constraint encoding each constraint entry as a relative oset
from the previous time point.
4.1.2 mRNA Analysis
The MEGPath [34] system was used to identify mRNA genes potentially involved
with the pathology. The MEGPath system was designed to identify sets of genes
that, as a group, are signicantly related to a known pathology pattern. The rst
step was to identify a subset of genes which were signicantly changing. Since most of
the genes change very little over time, the patterns should be found from genes with
more noticeable changes. Genes with fold changes that were changing signicantly
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were identied at each dose and time condition and considered signicant.
The MEGPath system uses the signicant genes and constraint pathology along
with the described NMF algorithm to identify underlying biological patterns. The
identied patterns are then used to nd genome wide coecients. These coecients
(C) relate each gene to each of the patterns (P ) and are used to identify sets of genes
that are signicantly related to the pattern. The gene sets used are from the curated
MSigDB [111] database allowing for annotations for each gene's function. Genes may
be contained in multiple gene sets. The gene sets are functionally related and are
not required to be co-expressed. An example of a pathology pattern and some of the
identied mRNA genes can be seen in Figure 4.2.
Figure 4.2: The dose 80 µg brosis pathology and signicantly related mRNA. The
brosis pathology was used as a constraint in the NMF algorithm for both miRNA
and mRNA. The mRNA were found to be related to brosis by both the pathology
and IPA.
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4.1.3 miRNA Analysis
The MEGPath system identies mRNA that are functionally involved with a con-
straint pathology. Unfortunately, the MEGPath system relies on functional annota-
tions from the MSigDB for each mRNA gene and there are currently no similar func-
tional annotation databases for miRNA. Our methodology identies miRNA that are
functionally involved with the pathology by utilizing known potential miRNA targets
and both mRNA and miRNA expression data to select pairs that show signs of being
regulated.
The described constrained NMF algorithm was used to relate the constraint
pathology to the miRNA. Patterns (P ) and each probe's corresponding coecients
(C) were computed from the time series miRNA microarray data. The rst pat-
tern was constrained to match the pathology. A probe's error was calculated as the
absolute dierence between the normalized reconstructed probe expression and the
normalized original probe expression.
Coecients corresponding to the constrained pathology pattern were considered
for signicance. The probe's error values were subtracted from the probe's coe-
cients to eliminate probes with high reconstruction error. This step reduces the op-
portunity for false positives generated from probes with noisy data. These modied
genome-wide coecients were then plotted to visibly check for a normal distribution
(Figure 4.4). A normal distribution was tted to the modied coecients and probes
with coecients with a probability less than 5% were kept. Only the coecients for
the pathology pattern were used. An example of a miRNA, let-7c, and related lung
brosis pathology can be seen in Figure 4.3.
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Figure 4.3: The dose 80 µg brosis pathology and signicantly related miRNA. The
brosis pathology was used as a constraint in the NMF algorithm for both miRNA
and mRNA.
4.1.4 Integrated Analysis
After identifying both mRNA and miRNA for further study, an integrated analysis
was applied. The integrated analysis was performed in two steps.
Potential target pairs were identied from databases. Three databases were
used: miRTarBase [56], miRecords [131], and TargetScan [73]. The TargetScan
database provides predicted regulatory miRNA/mRNA pairs. Both miRTarBase and
miRecords provide a mix of published validated pairs as well as predicted pairs. Both
validated human and mouse pairs were kept. The miRBase [48] website was used to
translate a probe's gene name into the most recent form.
The potential target pairs were then ltered according to the gene expression data.
Traditionally, a negative correlation analysis is performed as the miRNA and mRNA
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brosis pathology pat-
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Error values were subtracted from coecients making some be less than 0. A normal
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tted to the data.
expressions should be in opposite directions to signify regulation. Each miRNA may
target many mRNA; hence, over the course of time a miRNA's expression may be
changing to help regulate multiple mRNA and not be \opposite" of a targeted mRNA.
In addition, the discrete time points of time series data may miss critical moments
where a miRNA's expression changes. These issues were addressed by using the
second derivatives of the fold change. The second derivative is the \change of the
change", or given a gene G's fold change Gi at times i = 1 : : : (n  1):
G0i = (Gi+1  Gi)  (Gi  Gi 1):
The second derivative is not dened for the rst time point so the rst fold change is
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duplicated:
G00 = (G1  G0)  (G0  G0) = (G1  G0):
A miRNA/mRNA pair are considered targeted pairs if the second derivatives at
the same time point are opposite signs; hence, for miRNA R and mRNA M to be a
targeted pair:
9 i = 0 : : : (n  1) where R0i M 0i  0:
An example of target pairs, between let-7c and three mRNA, found through this
analysis can be seen in Figure 4.5. The target pairs have diering second derivatives
in at least one time point.
Figure 4.5: The miRNA let-7c was found to be signicantly related to the brosis
pathology. The mRNA were found to be related to brosis by both the pathology
and IPA. All mRNA and let-7c were identied as target pairs, with diering second
derivatives in at least one time point.
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Table 4.1: mRNA genes that were found to be signicantly related to the time series
dose 80 µg brosis pathology. Genes were ltered by IPA to be involved in brosis.
ACTC1 EGFR LGALS3 S100A4
ADORA1 EGR1 LGMN SELE
ADORA3 F11 MMP8 SELP
ADORA2B FAS MMP9 SERPINE1
AGO1 FCGR2B MMP12 SLC4A1
ARG1 FN1 MMP13 SLC8A1
ARID4A GCLC MMP14 SMAD4
ATF3 GSK3B MYD88 SMURF2
BDKRB2 HBEGF NFKBIA SOAT1
BMPR2 HIF1A OSM SOCS1
C3 HMGCS1 PDGFRA SOCS3
CCL2 HPX PLA2G10 SOD2
CCL17 IGF1 PLAT STAB1
CCL24 IL5 PLAUR TIMP1
CCR1 IL6 PROC TLR2
CD74 IL11 PTGIR TNF
CEBPB IL12B PTGS2 TNFAIP3
CSF3 IL1B PTK2 TNFRSF1B
CTSB IL1R1 PTX3 TNNC1
CTSK IL1RN RASSF1 VEGFA
CX3CL1 INHBA RELB VIM
DAG1 KCNN4 RGS16 WRN
EDNRB
4.2 Results and Implementation
Results were obtained from an in vivo dose-response time series multi-wall carbon
nano-tube (MWCNT) aspiration exposure experiment [96]. The experimental results
indicated lung damage, inammation, and brosis.
All code was written in Java and the analyses were run on a standard laptop
computer.
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Table 4.2: mRNA genes that were found to be signicantly related to the time series
dose 40 µg inammation pathology. Genes were ltered by IPA to only those involved
in inammation.
ABCC1 ADAM8 ADORA1 ADORA3 AGT
AGTR2 AHSG AIF1 ANGPTL2 ANXA1
AOC3 BLNK C3AR1 CAPG CCDC88A
CCL2 CCL3 CCL4 CCL5 CCL7
CCL17 CCL20 CCL24 CCR1 CD9
CD14 CD44 CD63 CD69 CD74
CDKN1A CEBPB CHRNA7 CLEC5A CLEC7A
CSF3 CX3CL1 CXADR CXCL1 CXCL2
CXCL3 CXCL5 CXCL10 CXCL12 CYBA
CYSLTR1 DPP4 EGR1 EPAS1 FCER1G
FCGR2B FN1 FOS FOXP3 GHRL
GIT2 GNAI2 HYAL1 IGF1 IKBKG
IL5 IL6 IL16 IL24 IL12B
IL1B IL1R1 IL1RN IL23A IL2RA
INHBA ISG15 ITGB2 ITGB6 ITGB7
LGALS3 LITAF LUM LY75 MCL1
MDK MEFV MMP8 MMP9 MMP14
MSR1 MYD88 NAD+ NCKAP1L NCL
NFIL3 NPY NR1D1 NR2C2 OLR1
OSM PIK3R5 PLA2G7 PLA2G10 PLAUR
PPBP PRG2 PRKCD PROC PROCR
PTGER3 PTGS1 PTGS2 PTN PTPN2
PTX3 RGS1 RIPK3 S100A8 SDC4
SELE SELP SERPINE1 SFRP1 SLC11A1
SOCS1 SOCS3 SPACA3 SPHK1 SPP1
STEAP2 TNF TNFAIP3 TNFRSF4 TNFRSF9
VAV1 VEGFA WNT5A XCR1
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4.2.1 Data
The data set consisted of dose-dependent time series mRNA and miRNA microarray
expression data. Microarray data came from 160 MWCNT exposed mice (C57BL/6J).
The doses were 0(dm), 10, 20, 40, or 80 µg of MWCNT. Total RNA was extracted
from the mouse lungs at 1, 7, 28, and 56 days post-exposure for each dose condition.
Agilent Mouse Whole Genome Arrays were used for mRNA expression proling. In
total the mRNA genome contained 41,059 probes and the miRNA genome consisted
of 484 probes. Our mRNA data has been deposited to the NCBI Gene Expression
Omnibus (GEO) repository with accession number GSE29042, miRNA data is in the
process of being deposited. We also maintain a website for browsing both data sets
on the web.1 The microarray data were log-transformed for analysis. In addition to
mRNA and miRNA data, 160 mice were used for quantitative inammation scores and
160 mice were used for quantitative brosis scores. Inammation scores were derived
from the analysis of BAL uid [96]. The average thickness of the alveolar connection
tissue was used for brosis scores. These were found from the morphometric analysis
of Sirius Red staining for connective tissue [83].
4.2.2 Signicantly Changing Probes
Signicant mRNA and miRNA probes were found using the same procedure. Missing
data were imputed using the K-means nearest neighbor algorithm as implemented
by the impute.knn function in the impute R package from Bioconductor (Seattle,
WA). Using the Bioconductor package, a set of dierentially expressed genes for each
dose and time point were identied by performing a two-class unpaired Signicance
Analysis of Microarrays (SAM) between the treated samples and the dose zero samples
1http://www.mwcnttranscriptome.org
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from the corresponding time point. A threshold delta value was chosen to produce a
false discovery rate of 1%(mRNA) and 5%(miRNA) using the ndDelta function from
the same package. The list of signicant probes was ltered by only keeping probes
that were at least 1.5 fold up- or down-regulated. Fold changes were computed from
the data before imputation of missing values.
4.2.3 mRNA Results
Gene sets signicantly related to the time series 80µg dose brosis and the time series
40 µg dose inammation pathologies were obtained from the mRNA microarray data.
The SAM analysis was run on all conditions to obtain signicantly changing mRNA at
either a dose or time condition. In addition, genes signicant with linear models [49]
were used. The 2,996 signicant probes were used with the NMF algorithm to identify
three underlying patterns from the four time points for both pathologies. Genome-
wide coecients were then found relating each gene to the pathologies, coecient
error inuence was minimized by identifying sets of genes. All gene sets were from
the MSigDB curated databases.
The brosis pathology coecients were used to identify signicantly represented
sets of genes, identifying 30 gene sets found from the C2 database and 39 sets from
the C5 database. The inammation pathology coecients were used to identify sig-
nicantly represented sets of inammation genes, with 50 gene sets found from the
C2 database and 61 sets from the C5 database. Many genes were found in multiple
gene sets, two such genes CCL2 and VEGFA were validated in vitro as changing
expression when exposed to MWCNT [37].
All genes from the gene sets associated with the brosis pathology were screened
through Ingenuity Pathway Analysis (IPA), an online curated literature based tool
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Table 4.3: miRNAs associated with the brotic pathology and their associated mRNA
binding partners. Each pair passes the second derivative test. Signicantly changed
miRNAs are highlighted in bold.
miRNA miRTarBase, miRecords TargetScan
Experimentally Conrmed Predicted
let-7c-5p AGO1, IL6, RGS16,
PTK2 TNFAIP3, TNFRSF1B
miR-205-5p VEGFA IL1R1, PTX3
miR-23b-3p SMAD4 EDNRB, FAS,
GSK3B, IL11
miR-31-5p HIF1A, HBEGF
SELE
miR-326-3p AGO1 RASSF1
miR-328-3p AGO1
miR-330-3p AGO1, RASSF1
VEGFA
miR-34c-3p PDGFRA,
SERPINE1,
SMAD4
miR-375-3p KCNN4 BMPR2, EDNRB,
RGS16
miR-455-3p AGO1
miR-652-3p AGO1
miR-92b-3p
(ingenuity.com). The 89 mRNA genes related to brosis found by IPA were kept for
further analysis and are listed in Table 4.1. Likewise, genes from the inammation
associated gene sets were screened through IPA. The 125 mRNA genes related to
inammation are listed in Table 4.2.
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Table 4.4: miRNAs associated with the inammation pathology and their associated
mRNA binding partners. Each pair passes the second derivative test. Signicantly
changed miRNAs are highlighted in bold.
miRNA miRTarBase, miRecords TargetScan
Experimentally Conrmed Predicted
miR-1224-5p
miR-147-3p VEGFA
miR-188-5p
miR-290a-5p
miR-327
miR-3474
miR-380-3p
miR-449a-5p GNAI2,
SERPINE1
miR-494-3p TNFRSF9
miR-551b-3p
miR-667-3p
miR-696
miR-703
miR-877-5p
miR-881-5p
miR-92a-2-5p MCL1, WNT5A
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Table 4.5: All miRNAs signicantly changed from controls identied from mice ex-
posed to 10, 20, 40, or 80 µg MWCNT at 1, 7, 28, and 56 days post-exposure. There
were no signicant miRNAs identied at Dose 10.
miR-103 miR-1188 miR-125b-3p miR-125b-5p
miR-126-3p miR-129-5p miR-1306 miR-130b
miR-132 miR-142-5p miR-146a miR-146b
miR-147 miR-149 miR-15a miR-15a*
miR-15b miR-16 miR-16* miR-188-5p
miR-1892 miR-1897-5p miR-18b miR-1902
miR-1903 miR-1904 miR-1906 miR-1932
miR-1935 miR-1937c miR-195 miR-1951
miR-196a miR-196b miR-1982* miR-199a-3p
miR-199a-5p miR-200a miR-200b miR-21
miR-2132 miR-2133 miR-2140 miR-22
miR-221 miR-222 miR-223 miR-26b
miR-296-3p miR-297a miR-297c miR-29b*
miR-30c miR-30c-1* miR-30e miR-31
miR-322 miR-323-5p miR-327 miR-328
miR-330 miR-341 miR-342-3p miR-3470b
miR-3473 miR-34a miR-34b-3p miR-34c
miR-370 miR-382 miR-429 miR-434-3p
miR-449a miR-449b miR-449c miR-450a-3p
miR-466b-5p miR-466h miR-467e miR-467h
miR-471 miR-486 miR-669a miR-669e
miR-673-3p miR-679 miR-696 miR-711
miR-714 miR-720 miR-744 miR-92a*
4.2.4 miRNA and Integrated Results
The SAM analysis was performed on the miRNA microarray data and identied 92
probes which were signicantly changed in at least one dose time condition (Table 4.5).
The NMF algorithm was run with the 80 µg dose brosis time series constraint.
Three patterns were found over the four time points. Since individual miRNA were
being identied, the coecients relating miRNA to the brosis pattern were modied
by subtracting the reconstruction error to penalize noisy genes.
A normal distribution was tted to the modied coecients with a mean of
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0.318 and a standard deviation of 0.128. Coecients with scores greater than 0.5285
(p < 0:05) were considered to be related to the pathology and are listed in Table 4.3.
Similarly, the NMF algorithm was run with the 40µg dose inammation time se-
ries constraint. Three patterns were found over the four time points. The coecients
relating miRNA to the brosis pattern were modied by subtracting the reconstruc-
tion error to penalize noisy genes. A normal distribution was tted to the modied
coecients with a mean of 0.271 and a standard deviation of 0.0849. Coecients with
scores greater than 0.4108 (p < 0:05) were considered to be related to the pathology
and are listed in Table 4.4.
After identifying the signicant miRNA, potential mRNA targets were ltered
by using three databases. Additional databases could be used. Finally, potential
pairs needed to have a diering second derivative in at least one time point. Only
one of the miRNA signicant with the brosis pathology did not end with a target,
miR-92b. Two miRNA were both signicantly changed in the SAM analysis and
related to the pathology: miR-31 and miR-328. Only four of the miRNA signicant
with the inammation pathology had targets: miR-147-3p, miR-449a-5p, miR-494-
3p, and miR-92a-2-5p. Five miRNA changed signicantly in the SAM analysis and
were related to the inammation pathology: miR-147-3p, miR-188-5p, miR-327, miR-
449a-5p, and miR-696.
4.3 Discussion
This study presents a methodology for integrating both miRNA and mRNA time
series data along with quantitative pathology information for identifying important
miRNA regulated biological processes underlying pathogenesis. The use of a con-
strained NMF algorithm allows for the identication of miRNA signicantly related
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to the pathology while still allowing gene expression to be inuenced by multiple
functions. The integration of mRNA provides additional functional annotation infor-
mation from IPA and MSigDB. Potential miRNA regulated mRNAs can be identied
by the second derivative test, encompassing both negative correlation aspects and
temporal responses.
Our system has been able to identify pairs of miRNA and potentially regulated
mRNA. All of the identied miRNA were related to the quantitative pathology pat-
terns and potential regulators of mRNA identied with brosis or inammation. In
particular the miRNA let-7c may have implications in lung brosis [9] and was shown,
with potential mRNA targets, in Figure 4.5. Likewise, mir-31 has been shown to be
a involved in lung brosis regulation [133], suggesting an active role in attempting to
suppress MWCNT caused lung brosis. Other identied miRNA with potential lung
brosis involvement are mir-326 [26] and mir-375 [129]. In addition, miR-449a and
miR-92a have been shown to change expression with titanium dioxide nanoparticle
exposure and have potential involvement with lung inammation [51]. The predicted
miRNA /mRNA targets could be validated in vitro or biological connections explored
using IPA [36]. Although demonstrated on MWCNT toxicity data, this integrated
approach could be used in other applications.
4.4 Publications
Some the work described in this chapter has been published in proceedings of the
ACM International Conference on Bioinformatics and Computational Biology. In
addition, a journal manuscript has been prepared for submission to Bioinformatics.
J. Dymacek and N. L. Guo. Integrated mirna and mrna analysis of time series
microarray data. In Proceedings of the 5th ACM Conference on Bioinformatics, Com-
putational Biology, and Health Informatics, BCB '14, pages 122127, Newport Beach,
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Chapter 5
Results Analysis
5.1 Biological Validation of the MEGPath System
Integrating in vivo, in vitro studies, and in silico analysis is a recent endeavor in
toxicological sciences. Novel methods for the analysis of current in vivo data are
needed to develop predictive in vitro models so as to determine the toxicity prole of
multiple material variants, such as various types of carbon nano-tubes. By identifying
the leading gene sets of the signicant functions and pathways, our system can extract
genes that are strongly associated with the inammation and brosis pathologies and
that have potential involvement in inammation and collagen production. The use of
Ingenuity Pathway Analysis 1 allows for global analysis of our leading sets throughout
the body of accepted scientic literature so as to target our results to those genes
known to be involved in inammation and brosis.
1(Ingenuity RSystems, www.ingenuity.com)
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5.1.1 Ingenuity Pathway Analysis
Data were analyzed through the use of Ingenuity Pathway Analysis (IPA). A net-
work/My Pathway is a graphical representation of the molecular relationships be-
tween molecules. Molecules are represented as nodes and the biological relationship
between two nodes is represented as an edge (line). All edges are supported by at
least one reference from the literature, from a textbook, or from canonical informa-
tion stored in the Ingenuity R Knowledge Base. Human, mouse, and rat orthologs
of a gene are stored as separate objects in the Ingenuity R Knowledge Base but are
represented as a single node in the network. Nodes are displayed using various shapes
that represent the functional class of the gene product.
A total of 773 signicant inammation genes identied in the computational sys-
tem were subjected to an Inammatory Response Inammation overlay to determine
which genes in the signicant inammation leading set were directly involved in in-
ammation according to IPA (Table 5.2). A total of 890 signicant brosis genes were
subjected to an Organismal Injury and Abnormalities Fibrosis overlay to determine
which genes in the signicant brosis leading set were directly involved in brosis
according to IPA (Table 5.1). To determine the interactions between genes which
have only been experimentally observed in the lung, the Build-Trim tool of IPA was
used. Direct and indirect interactions were trimmed to a Condence Level of Experi-
mentally Observed, and Tissue & Cell Lines were trimmed to Organ Systems of Lung
and Cell Line as Lung Cancer Cell Line.
5.1.2 Cell Culture
Small airway epithelial cells (SAEC) were cultured in SABM media (Lonza) sup-
plemented with a SingleQuot Kit (Lonza). Cells were maintained at 37 C with 5%
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Table 5.1: mRNA genes that were found to be signicantly related to the time series
dose 80 µg brosis pathology. Genes were ltered by IPA to be involved in brosis.
ACTC1 ADORA1 ADORA2B ADORA3 ADRA2A
ARG1 BDKRB2 BMPR2 C3 CCL17
CCL2 CCL8 CCR1 CEBPB CXCL10
CXCL12 EDNRB EIF2C1 EPHA2 F11
FAS FCGR2B FLT3 FN1 GSK3B
HIF1A HMGCR HMGCS1 HPX IGF1
IL11 IL12B IL1B IL1R1 IL1RN
IL2RA IL5 IL6 IRF7 LGALS3
LYVE1 MDK MMP12 MMP13 MMP14
MX1 MYD88 OAS2 OSM PDE3A
PDPN PLA2G10 PROC PTGIR PTGS2
PTK2 S100A4 SELE SELP SMAD4
SMURF2 SOCS1 SSTR4 THBS1 TIMP1
TNF TNFAIP3 TNFRSF1B VEGFA
Table 5.2: mRNA genes that were found to be signicantly related to the time series
dose 40 µg inammation pathology. Genes were ltered by IPA to only those involved
in inammation.
ABCC1 ADORA2B ADORA3 AGT APP
C3AR1 CARD11 CCL2 CCL4 CCL5
CD14 CD44 CD48 CD86 CEBPB
CORT CTSD CTSS CXCL12 CYBA
EGFR FCER1G FCGR2B FN1 GHRL
GJA1 ICOS IGF1 IKBKG IL12B
IL1B IL1R1 IL1RN IL21R IL23A
IL24 IL2RA IL6 ITGB2 JUNB
MC2R MMP9 MYD88 NFKBIA OLR1
OSM PBK PGF PLA2G10 PLA2G7
PTGER3 PTGS1 PTGS2 RIPK3 SELP
SLC11A1 SOCS1 SOD2 SPHK1 SPP1
THBS1 TNF TNFAIP3 TNFRSF4 TNFRSF9
TNFSF10 VCAM1
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CO2.
Enzyme-Linked Immunosorbent Assay (ELISA)
SAEC were plated at 60,000 cells per well in a 24-well dish and grown at 37 C for
48 hours. Cells were serum starved overnight followed by exposure to 1 µg/ml or
2:5 µg/ml MWCNT for 24 hours. Conditioned media were collected and assayed for
vascular endothelial growth factor A (vegfa) and C-C motif chemokine 2 (ccl2 ) protein
expression levels using DuoSet ELISA Development Systems from R & D Systems
(Minneapolis, MN) according to manufacturer's protocol. Statistical analysis was
done using a two-sample t-test assuming unequal variances.
Cellular RNA isolation
RNA was isolated from SAEC using RNAprotect Cell Reagent and an RNeasy Mini
Kit from Qiagen according to the manufacturer's protocol (Qiagen, Valencia, CA).
RNA concentrations were determined using a NanoDrop 1000 Spectrophotometer
(NanoDrop Technologies, Wilmington, DE) and RNA quality was assessed using an
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA).
Real-Time Polymerase Chain Reaction
Total RNA (1 µg) was converted into complementary DNA (cDNA) using a High Ca-
pacity cDNA Reverse Transcription Kit from Applied Biosystems (Life Technologies,
Carlsbad, CA). All quantitative real-time PCR (qRT-PCR) reactions were performed
on a 7500 Real-Time PCR system from Applied Biosystems. Each treatment group
consisted of three biological replicates. qRT-PCR analysis for each biological repli-
cate was performed in triplicate, and the Ct values obtained were normalized to the
18s housekeeping gene. Validated gene expression assays from Applied Biosystems
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were employed to carry out the mRNA expression proling. The following gene ex-
pression assays were used: vegfa (Hs00900055 m1); ccl2 (Hs00234140 m1); and 18s
(Hs99999901 s1). Thermal cycling conditions were as follows: 50 C for 2 minutes,
95 C for 10 minutes, followed by 40 cycles of 95 C for 15 seconds and 60 C for 10
minutes.
5.1.3 Results
Identication of biological processes with expression patterns resembling
MWCNT-induced inammation or brosis pathology
The MEGPath system was used to identify genes and biological processes with tran-
scriptional activities, which matched the observed pathological patterns of lung in-
ammation or brotic collagen in the alveolar wall in the MWCNT-exposed mice.
The Gene Identication step found 2,996 unique probes which were signicantly up-
regulated or down-regulated using Signicance Analysis of Microarrays (SAM) or a
linear model showing signicant dose-response or dose and time interactions. Using
this set of 2,996 genes, quantitative BAL and pathological data of MWCNT-induced
inammation or quantitative morphometric analysis of brosis were used as input pat-
terns to nd gene coecients for reconstruction of the gene expression. Specically,
results for three sets of data were found, two sets relating to brosis (morphometri-
cally determined changes in collagen within the alveolar wall) [83] and one relating
to inammation (BAL) [96]. Pathology data for brosis at dose 80µg across the four
time points was tted as an input pattern. The computational system found 69 total
signicant leading sets, the subset of genes that was used to compute the Functional
Process Evaluation (FPE) score, representing the level of correlation with the brosis
morphometric data for each biological process in the databases. Morphometric data
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for brosis occurring on day 56 across four doses was t in the computational system
with 85 signicant leading sets found. Lastly, inammation BAL scores at dose 40 µg
across four time points was used, and 111 leading sets were found to be signicantly
correlated with the inammation pattern.
Example results for each of the pathology data are shown in Figure 5.1. The
average of the mRNA expression of genes in the leading set closely resembled the
pathology data, indicating that in general, the transcriptional activities of the lead-
ing set genes correlated with changes in the pathology. The leading set Reactome
Hemostsasis (Figure 5.1E) was found in the C2 Canonical Pathways database and
consisted of 147 genes. The leading sets of Immune System Process (Figure 5.1C)
and Response To External Stimulus (Figure 5.1F) were found in the C5 database
and consisted of 163 genes and 103 genes. Ccl2 (Figure 5.1A) was contained in the
leading set of Immune System Process. Although the ccl2 expression does not exactly
follow the pattern, the average of all gene expression in the leading set does. The
same can be seen for vegfa (Figure 5.1B). Importantly, our computational system
does not constrain genes to being in only one leading set, allowing for genes to be
involved in multiple processes. For instance, ccl2 was found to be involved in both
MWNCT-induced brosis (Figure 5.1F) and inammation (Figure 5.1D).
Determination of genes functionally involved in inammation and brosis
To determine which genes were signicantly altered in response to MWCNT expo-
sure, leading set genes which attained a fold change of 1.5-fold or greater were input
into IPA to determine if they were functionally involved in inammation or brosis
according to currently accepted literature.
The inammation and brosis biological processes consisted of 773 and 890 unique
genes, respectively, identied to be signicantly altered ( 1:5 fold change) after
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Figure 5.1: Three leading sets found to be signicant in a search of the C5 and C2
Canonical Pathway databases using pathological data. Computations were based on
the observed experimental data points only; lines have been added to emphasize the
patterns used in the computational system. For each pathway, (D) Immune System
Process , (E) Reactome Hemostasis, and (F) Response to External Stimulus, the
average of all the genes in the leading set shows strong similarity to the pathology
data. Expression fold change values are shown for ccl2, which was found in the leading
sets in (D) and (F), at (C) day 56 and (A) dose 40. Vegfa, found in the leading set
from (E), fold change is shown in (B).
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MWCNT exposure (signicant inammation) with a false discovery rate (FDR) of
1% in SAM analysis. Of the 773 signicant inammation genes, 67 were determined to
be directly involved in inammation by IPA (Table 5.2). Of the 890 signicant brosis
genes, 69 were determined to be directly involved in brosis by IPA (Table 5.1).
A heat map of gene expression for the 67 signicant inammation genes (Fig-
ure 5.2) suggested the up- and down-regulation of multiple genes in response to
MWCNT exposure. Expression of c3ar1, fcgr2b, pbk, pla2g10, il2ra, il1rn, ptgs1,
cd14, igf1, ccl2, ccl4, il1b, pla2g7, tnfrsf4, ghrl, slc11a1, tnfaip3, cd44, adora2b, gja1,
tnf, ptgs2, junb, cd86, cyba, fcer1g, ripk3, and socs1 was up-regulated on all days
at almost all doses. Expression of itgb2, icos, il12b, ctss, ctsd, cd48, and il21r was
down-regulated at day 1 but increased in expression at almost all doses on days 7 and
28 and all doses on day 56. Expression of fn1, osm, selp, thbs1, pgf, tnfsf9, adora3,
il23a, myd88, il1r1, sod2, cebpb, and nfkbia was up-regulated at all doses on day 1
with a decrease in expression over time and down-regulation at most doses on day 56.
Spp1 was highly up-regulated on all days, particularly at doses 40 and 80µg, while
il6 was highly up-regulated on Day 1 and had a sustained increase in expression over
time. Expression of ptger3, ikbkg, cxcl12, ccl5, tnfsf10, card11, il24, mc2r, cort, mmp9,
vcam1, agt, sphk1, app, egfr, and abcc1 was down-regulated across all days at most
doses.
Of the 69 signicant brosis genes (Figure 5.3), il1rn, lgals3, pla2g10, ccl17,
adra2a, cxcl12, fcgr2b, s100a4, igf1, mx1, ccl8, arg1, mmp13, il1b, sele, hpx, timp1,
ccl2, adora2b, hmgcr, hmgcs1, tnfaip3, tnfrsf1b, adora3, c3, tnf, tpgs2, and hif1a were
up-regulated on all days at almost all doses. Expression of il12b, t3, mdk, adora1,
and il2ra was decreased on day 1 but increased over time, while expression of pdpn,
myd88, il1r1, cebpb, mmp14, fn1, socs1, irf7, selp, osm, thbs1, oas2, ptgir, and sstr4
was increased on day 1 and decreased over time. Il6, cxcl10, ccr1, and mmp12 were
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highly expressed on day 1 and remained up-regulated over time, while fas, smad4,
vegfa, eif2c1, epha2, ptk2, gsk3b, proc, f11, lyve1, pde3a, ednrb, bdkrb2, actc1, bmpr2,
and smurf2 were down-regulated across all days at almost all doses.
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Figure 5.2: Heatmap representation of genes signicantly altered above 1.5-fold with
an FDR of 1% in SAM analysis in inammation. In vivo gene expression of 67
signicant inammation genes across days 1, 7, 28 and 56 at doses 10, 20, 40, and
80 µg.
Using IPA and these 67 inammation genes and 69 brosis genes, we determined
those genes which were signicantly involved in IPA Function and Disease Annota-
tions associated with MWCNT-induced brosis. A recent report by Mishra et al. [84]
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Figure 5.3: Heatmap representation of genes signicantly altered above 1.5-fold with
an FDR of 1% in SAM analysis in brosis. In vivo gene expression of 69 signicant
brosis genes across days 1, 7, 28 and 56 at doses 10, 20, 40, and 80 µg
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determined that low, physiologically relevant doses of MWCNT equivalent to those in
our mouse study could signicantly elevate the levels of transforming growth factor 
(tgf-) and matrix metalloproteinase-9 (mmp-9 ) in lung epithelial cells, as well as in-
crease mechanisms of collagen production and cellular activation. Therefore, we used
IPA to determine which genes in our signicant inammation and brosis gene sets
were involved in these processes (Tables 5.1 and 5.2). Many inammation genes were
involved in general cell activation by functional association with the IPA function and
disease annotations, including Cell Movement, Proliferation of Cells, and Morphology
of Cells. Genes found in the signicant inammation set were also involved in the
function and disease annotations, including Injury of Lung (ccl2, cd14, il6, il1r1, olr1,
ptgs1, ptgs2, selp, sphk1, and tnf ), Degradation of Connective Tissue (fn1, il6, il1b,
il1rn, osm, ptgs1, ptgs2, and tnf ), as well as the signaling pathway vegf Signaling
(pgf ). No signicant inammatory genes were found in the tgf- signaling pathway
according to IPA. Many brosis genes were also involved in the general cell activa-
tion function and disease annotations, such as Cell Movement, Proliferation of cells,
and Morphology of Cells. Several genes in the signicant brosis set were involved
in the function and disease annotations, including Injury of Lung (adra2a, c3, ccl2,
hif1a, il5, il6, il1r1, mmp12, ptgs2, selp, tnf, and vegfa), Degradation of Connective
Tissue (fcgr2b,fn1,il6, il1b, il1rn, mmp13, osm, ptgir, tnf, and tnfrsf1b), as well as
the signaling pathway vegf Signaling (actc1, hif1a, ptk2, and vegfa). Interestingly,
three genes in the signicant brosis set, bmpr2, smad4, and smurf2, were involved in
the IPA tgf- Signaling pathway, again suggesting that tgf- signaling may play an
important role in the progression of brosis and that the computational system was
ecient in determining those biological processes which were functionally related to
MWCNT-induced inammation and brosis. An additional analysis of the signicant
inammation (Figure 5.4) and brosis (Figure 5.5) genes by IPA determined those
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genes that have been experimentally shown to have an interaction specically in the
lung.
Figure 5.4: IPA analysis of the 67 signicant inammation genes to determine those
interactions, which specically occur in the lung.
5.1.4 Vegfa and ccl2 in vivo and in vitro RNA expression
The 67 inammation genes and 69 brosis genes were ranked by their frequency of
inclusion in the biological processes signicantly correlated with the pathological data
(Figure 5.6). Two genes, ccl2 and vegfa, were selected for in vitro validation. Ccl2
was the top ranked gene that was involved in the most biological processes correlated
with the inammation and among the top 20 genes involved in the most biological
processes correlated with the brosis. Consistently, in the IPA lung interaction net-
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Figure 5.5: IPA analysis of the 69 signicant brosis genes to determine those inter-
actions, which specically occur in the lung.
works (Figure 5.4 and 5.5), ccl2 is in a hub that interacts with both tnf and il1
hubs in the inammation and brosis networks. Vegfa was found to be functionally
associated with the brosis leading set and is integral in the formation of new blood
vessels [38].
Neovascularization is necessary for the formation of brotic tissue, and vegf has
been suggested as a serum biomarker for ranking the severity of idiopathic pulmonary
brosis [108, 118, 3]. In a separate study, angiogenesis was observed after MWCNT
exposure in human endothelial cells and in a coculture of both human epithelial and
endothelial cells following epithelial exposure [107]. Based on these results, ccl2 and
vegfa were analyzed for their in vitro mRNA and protein expression levels following
MWCNT exposure to validate the in vivo analysis.
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Figure 5.6: (A) Ranking of signicant brosis genes by their frequency of appearance
in biological processes signicantly correlated with histopathological data. (B) Rank-
ing of signicant inammation genes by their frequency of appearance in biological
processes signicantly correlated with histopathological data.
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In vivo mRNA levels of vegfa showed stable expression levels across all days and
doses with a signicant decrease in expression on day 56 at dose 40µg (Figure 5.1B)
and closely resembled the time-course of the morphometric collagen score data and
leading set average of the biological process Reactome Hemostasis (Figure 5.1E). Ccl2
showed a consistent dose-dependent increase in mRNA expression on all days with
signicant increases at all doses on day 1, doses 20, 40, and 80 µg on day 7 and doses
40 and 80 µg on day 56 (Figure 5.1C). Ccl2 in vivo mRNA expression data closely
resembled the brosis day 56 dose-response morphometric analysis and leading set
average of biological process Response to External Stimulus (Figure 5.1F) and was
similar to the inammation BAL pattern and leading set average for Immune System
Process (Figure 5.1D).
To assess the ability of MWCNT to induce similar RNA expression changes in
vitro, SAEC were exposed to MWCNT at either 1 µg/ml (approximately equivalent
to the in vivo dose of 20-40 µg [96]) or 2:5µg/ml (approximately equivalent to the
in vivo dose of 80 µg [96]) for 24 hours, and their mRNA expression levels analyzed.
MWCNT exposure at both 1 µg/ml and 2:5µg/ml exposure levels induced modest but
signicant increases in vegfa mRNA expression in vitro in a dose-dependent manner.
MWCNT exposure at both 1 µg/ml and 2:5 µg/ml levels induced an increase in ccl2
mRNA expression with a signicant increase at 1 µg/ml.
5.1.5 Vegfa and ccl2 in vitro protein expression
To determine if the change in in vitro mRNA expression levels after exposure to
MWCNT resulted in an increase in protein expression, conditioned media from cells
exposed to either 1 µg/ml or 2:5 µg/ml MWCNT for 24 h was collected and analyzed
by ELISA for vegfa and ccl2 protein expression. Vegfa showed signicant increases
78
in protein expression levels over control after 24 h of MWCNT exposure. Ccl2 also
showed signicant increases in protein expression levels after 24 h of exposure. This
demonstrated that the increase in mRNA expression levels of vegfa and ccl2 after
MWCNT exposure in vitro resulted in a concordant increase in protein expression
and indicated that a similar increase may occur after in vivo exposure.
5.1.6 Discussion
Using a novel computational system, the correlation of global mRNA expression pro-
les to the changes in BAL score and morphometric analysis was analyzed. This iden-
tied transcription-related biological processes with expression patterns resembling
the pathological patterns of inammation and brosis in MWCNT-exposed mice, al-
lowing for the identication of critical toxicity pathways and potential mechanisms for
intervention. The results showed that this systematic analysis could identify relevant
genes and pathways in MWCNT-induced lung injury from in vivo studies, which were
further validated in in vitro experiments.
The use of IPA to determine if genes signicantly altered in the leading sets were
involved in inammation or brosis allowed for an in depth analysis based upon data
derived from relationships between genes and disease states taken from the currently
accepted literature knowledge base. These analyses were rooted in and veried by ex-
perimental results collated from numerous sources. A total of 67 signicantly altered
genes were determined by IPA to be directly involved in the inammatory process
while 69 signicantly altered genes were determine by IPA to be directly involved in
brosis. Of the signicantly altered genes, two genes, ccl2 and vegfa, were chosen to
determine their in vivo and in vitro expression levels due to their roles in the cell
during the development of inammation and brosis as well as their rankings during
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gene proling.
The dose-dependent increase in ccl2 mRNA expression at all days and doses in
vivo suggests its role in the initial inammatory process. Although the in vivo mRNA
levels of vegfa remained relatively constant across all days and doses, the in vivo
protein levels are unknown and may enhance collagen production. In vitro levels of
ccl2 and vegfa mRNA also increased with increasing dose, reecting what is seen in
the in vivo analysis. In vitro analysis of the protein levels of ccl2 and vegfa suggests
that even modest increases in mRNA levels were able to signicantly up-regulate
protein expression, and a similar increase in protein expression may occur in vivo.
The analogous changes to vegfa mRNA levels in vitro, with subsequent increases in
protein levels, suggest that MWCNT may have a similar eect in vitro to that seen in
vivo. This may allow for potentially signicant cellular processes to be identied by
computational means and for the analysis of the mechanisms and signaling cascades
behind MWCNT-induced eects to be validated in an in vitro manner.
5.2 Integrated mRNA and miRNA Analysis
mRNA signicantly associated with MWCNT-induced inammatory and brotic patho-
logical patterns and functionally involved in lung inammation and brosis in IPA
analysis were used to identify miRNA targets and mRNA/miRNA regulatory net-
works. There were two sets of miRNA used in the analysis. One set consists of
miRNA that were signicantly changed after MWCNT exposure and found by IPA
to be functionally involved in inammation and brosis. The second set of miRNA
were associated with the pathological patterns [35]. Both sets were used in the in-
tegrated miRNA/mRNA analysis. Potential mRNA targets of signicant miRNA
were identied using the miRTarBase [56], miRecords [131], and TargetScan [73]
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databases. To be considered as a potential mRNA/miRNA target pair, the expres-
sion proles of each mRNA/miRNA pair needed to have a diering second derivative
in at least one time point, indicating a divergence in expression during miRNA reg-
ulated post-transcriptional activities. The integrated pathways of identied miRNAs
and mRNAs were then analyzed and visualized with IPA. The results are provided
in Tables 5.3-5.5, listing miRNA/mRNA regulations identied through our analysis
that were either experimentally conrmed (Column 3 in Tables 5.3-5.5) or predicted
as highly conserved target pairs (Column 4 in Tables 5.3-5.5). In comparison, the
miRNA-mediated regulations retrieved from the IPA database are listed in the last
column in Tables 5.3-5.5. It is worth noting that the regulations stored in the IPA
database may or may not overlap with the results identied with our algorithms.
5.2.1 Inammation pathology
In total, 16 miRNA were associated with the inammatory pathology, ve of which
(mir-147-3p, mir-188-5p, mir-327, mir-449a-5p, and mir-696 ) were signicantly up-
or down-regulated after MWCNT exposure. Four miRNAs, mir-147-3p, mir-449a-
5p, mir-494-3p, and mir-92a-2-5p, had predicted or experimentally conrmed mRNA
targets that were also associated with the inammatory pathology (Table 5.4). The
integrated inammation pathway based upon miRNAs and mRNAs in Table 5.4 is
shown in Figure 5.7. The identied relationships highlighted with a red solid/dash
line were not available in the IPA database. Specically, a regulatory relationship
between mir-147-3p and vegfa identied in our analysis was experimentally conrmed
[135] (designated as a solid red line in Figure 5.7). Our analysis also predicted highly
conserved target pairs between mir-92a-2-5p and mcl1 and wnt5a (dashed red lines in
Figure 5.7). The gene expression direction (up- or down-regulation relative to control)
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Table 5.3: miRNAs associated with the brotic pathology and their experimentally
conrmed and predicted mRNA binding partners. Signicantly changed miRNAs are
highlighted in bold.
miRNA Experimentally TargetScan IPA
Conrmed Predicted Relationships
(miRTarBase, (highly conserved)
miRecords)
let-7c-5p AGO1 [53], IL6, RGS16, FAS, HBEGF,
PTK2 [53] TNFAIP3, IL6 [112], RGS16,
TNFRSF1B TNFRSF1B
miR-205-5p VEGFA [135] IL1R1, PTX3 IL1R1, SMAD4
miR-23b-3p SMAD4 [99] EDNRB, FAS, FAS, IL11,
GSK3B, IL11 GSK3B,
TNFAIP3
miR-31-5p HIF1A [104], HBEGF EDNRB, IL1R1
SELE [109] HBEGF
miR-326-3p AGO1 [53] RASSF1 RASSF1,
TNFAIP3
miR-328-3p AGO1 [53] TNFRSF1B
miR-330-3p AGO1 [53], RASSF1 BMPR2
VEGFA [135]
miR-34c-3p PDGFRA,
SERPINE1,
SMAD4
miR-375-3p KCNN4 [124] BMPR2, EDNRB, BMPR2,
RGS16 RGS16
miR-455-3p AGO1 [53]
miR-652-3p AGO1 [53]
miR-92b-3p BMPR2 [15], EDNRB
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Table 5.4: miRNA associated with the inammatory pathology and their experimen-
tally conrmed and predicted mRNA binding partners. Signicantly changed miRNA
are highlighted in bold.
miRNA Experimentally TargetScan IPA
Conrmed Predicted Relationships
(miRTarBase, (highly conserved)
miRecords)
miR-1224-5p
miR-147-3p VEGFA [135]
miR-188-5p
miR-290a-5p
miR-327
miR-3474
miR-380-3p
miR-449a-5p GNAI2,
SERPINE1
miR-494-3p TNFRSF9 SERPINE1,
WNT5A
miR-551b-3p
miR-667-3p
miR-696
miR-703
miR-877-5p
miR-881-5p
miR-92a-2-5p MCL1, WNT5A
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at doses 10, 20, 40 or 80 µg MWCNT on post-exposure Day 7 are shown for each
mRNA and miRNA. This time point was chosen because quantitative bronchoalveolar
lavage scores from post-exposure Day 7 [83, 96] were the peak of the inammation
pathology.
Figure 5.7: Regulatory network of mRNAs and miRNAs transcriptionally related to
the dose 40 post-exposure bronchoalveolar lavage inammatory pathological pattern.
5.2.2 Fibrosis pathology
Among the 12 miRNAs associated with the brotic patterns, two miRNAs (mir-31-5p
andmir-328-3p) were signicantly (FDR< 5 %; SAM analysis) up- or down-regulated
after MWCNT exposure (Table 5.3). All 12 miRNAs had at least one mRNA tar-
get as based upon the miRTarBase, miRecords, TargetScan, or IPA databases (Ta-
ble 5.3). The integrated brotic pathway based upon miRNAs and mRNAs in Ta-
ble 5.3 is shown in Figure 5.8. In addition to the functional relationships found by
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IPA, our system identied experimentally conrmed regulations between ago1 and
let-7c-5p, mir-455-3p, mir-652-3p, mir-326-3p, mir-328-3p, and mir-330-3p [53] and
between vegfa and mir-330-3p [135]. Our system predicted highly conserved target
pairs between ednrb and mir-375-3p and mir-23b-3p; rassf1 and mir-330-3p; and
mir-34c-3p and pdgfr, smad4, and serpine1. The gene expression direction (up- or
down-regulation relative to control) at doses 10, 20, 40 or 80 µg MWCNT at post-
exposure Day 56 are shown for each mRNA and miRNA. This time point was chosen
because quantitative morphometric analysis of Sirius Red staining for collagen at Day
56 [83] were the peak of the brosis pathology.
Figure 5.8: Regulatory network of mRNAs and miRNAs transcriptionally related to
the dose 80 Sirius Red staining brotic pathological pattern.
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5.2.3 Ingenuity Pathway Analysis
Next, we used the set of mRNAs associated with the MWCNT-induced brotic patho-
logical patterns and functionally involved with brosis in IPA analysis to identify their
miRNA regulators. A total of 10 miRNAs were identied as potentially involved in
MWCNT-induced brosis (Table 5.5). Among them, seven miRNAs (mir-125b-5p,
mir-126a-3p, mir-16-5p, mir-199a-5p, mir-21-5p, mir-30c-5p, and mir-322 ) had a sig-
nicant (FDR < 5 %; SAM analysis) expression change after MWNCT exposure. All
10 miRNAs had at least one mRNA target based upon the miRTarBase, miRecords,
TargetScan, or IPA databases. The integrated brotic pathway for the miRNAs and
mRNAs listed in Table 5.3 is shown in Figure 5.9. In addition to the functional re-
lationships retrieved with IPA, our analysis identied numerous post-transcriptional
regulations that have been previously experimentally conrmed, including regulatory
relationships between mir-125-5p and il1rn [54], tnf [122], tnfaip3 [68], and mmp13
[132]; mir-126a-3p and vegfa [144]; mir-18a-3p and hif1a [50], smad4 [29], and hmgcs1
[50]; mir-26a-5p and egr1 [21], smad4 [30], gsk3b [87], il6 [134], ago1 [53]; mir-21a-5p
and fas [100], bmpr2 [94], egfr [143], plat, ptx3, tnfaip3, ccr1 [117], vegfa [79], mmp9
[89], ptk2 , arid4a [43], among many others listed in Table 5.5 (highlighted with solid
red lines in Figure 5.9). Our analysis predicted highly conserved target pairs between
mir-18a-3p and igf1 and tnfaip3 ; mir-322-5p and ptgs2, vegfa, kcnn4, cxcl1, and
smurf2 ; mir-30c-5p and ednrb; and mir-26a-5p and ptx3 (designated by dashed red
lines in Figure 5.9). The gene expression direction (up- or down-regulation relative
to control) at doses 10, 20, 40, or 80 µg MWCNT at post-exposure Day 56 are shown
for mRNAs and miRNAs in Figure 5.9.
These results indicate that our algorithms could identify miRNA-mediated post-
transcriptional regulations in MWCNT-treated mice, either experimentally conrmed
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Table 5.5: miRNAs associated with brosis based upon IPA analysis and their ex-
perimentally conrmed and predicted mRNA binding partners. Signicantly changed
miRNAs are highlighted in bold.
miRNA Experimentally TargetScan IPA
Conrmed Predicted Relationships
(miRTarBase, (highly conserved)
miRecords)
miR-125-5p IL1RN [54], BMPR2, SMAD4, BMPR2, SMAD4,
MMP13 [132], TNFRSF1B, TNFRSF1B
TNF [122], VEGFA , TNFRSF1B
TNFAIP3 [68]
miR-126a-3p VEGFA [144]
miR-141-3p CSF3 EGFR, HMGCS1,
TNFAIP3
miR-16-5p EGFR [103], KNCC4 [103], CXCL1 AGO1, IGF1,
SMURF2 [14], PTGS2 [103]
VIM [103], VEGFA
miR-18a-5p HIF1A [50], IGF1,
HMGCS1 [50], TNFAIP3
SMAD4 [29]
miR-199a-5p HIF1A [98], SMAD4 [142] GSK3B, VEGFA, AGO1, EDNRB,
SERPINE1 GSK3B, VEGFA,
SERPINE1
miR-21-5p ARID4A [43],CCR1 [117], SMURF2,
BMPR2 [94], EGFR [143], TNF [140]
MMP9 [89], PLAT [117],
PTK2 [43], PTX3 [117],
FAS [100], VEGFA [79],
TNFAIP3 [117]
miR-26a-5p AGO1 [53], EGR1 [21] MMP14, PTGS2, IGF1
GSK3B [87],IL6 [134] PTX3
SMAD4 [30]
miR-30c-5p AGO1 [53], ARID4A, ARID4A
SOCS1 [141], ACTC1, IGF1 ACTC1, IGF1,
VIM [14] EDNRB, IGF1 SERPINE1
mir-322 CX3CL1, KCNN4,
PTGS2, VEGFA,
SMURF2
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Figure 5.9: Regulatory network of mRNAs transcriptionally related to the dose 80 Sir-
ius Red staining brotic pathological pattern and miRNAs experimentally validated
to be involved in brosis according to the Ingenuity RKnowledge Base.
interactions or highly conserved target pair predictions, many of which were not avail-
able in the Ingenuity RKnowledge Base. The identied miRNAs and mRNAs were
signicantly associated with MWCNT-induced pathological patterns and/or signi-
cantly up- or down-regulated in the mouse lung following MWCNT exposure, indicat-
ing their potential involvement in pathogenesis and utility as biomarkers for disease.
The integrated pathway analysis of miRNA and mRNA and the revealing of their
regulatory interactions further elucidated their functional roles in molecular disease
mechanisms.
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5.2.4 Potential Signaling Pathways in MWCNT-induced Lung
Inammation and Fibrosis
To determine signaling pathways potentially involved in the inammatory and -
brotic pathological responses to MWCNT exposure, all functionally related mRNAs
and miRNAs were analyzed by IPA using a Core Analysis. The top ve canon-
ical pathways signicant to the mRNAs and miRNAs found in the integrated in-
ammation analysis (Table 5.4) were Axonal Guidance Signaling, IL-6 Signaling,
Corticotropin Releasing Hormone Signaling, Ovarian Cancer Signaling, and Hepatic
Fibrosis/Hepatic Stellate Cell Activation. The top ve canonical pathways signi-
cant to the mRNAs and miRNA found in the integrated brosis analysis using the
NMF algorithm (Table 5.3) were Hepatic Fibrosis/Hepatic Stellate Cell Activation;
Role of Osteoblasts, Osteoclasts, and Chondrocytes in Rheumatoid Arthritis; NF-B
Signaling; Role of Macrophages, Fibroblasts, and Endothelial Cells in Rheumatoid
Arthritis; and HMGB1 Signaling. The top ve canonical pathways signicant to the
mRNAs and miRNAs found in the integrated brosis (IPA) analysis (Table 5.5) were
Hepatic Fibrosis/Hepatic Stellate Cell Activation; Role of Osteoblasts, Osteoclasts,
and Chondrocytes in Rheumatoid Arthritis; Colorectal Cancer Metastasis Signaling;
ILK Signaling; and Granulocyte Adhesion and Diapedesis. These results suggest that
the miRNA and mRNA regulatory networks identied in our analysis are reective
of the inammatory response and tissue remodeling biological processes during the
onset and progression of brosis following MWCNT exposure.
5.2.5 Discussion
After we used the second derivative analysis of expression proles to identify po-
tential regulatory miRNA/mRNA pairs, mRNA and miRNA functional relationships
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were assessed through the Ingenuity RKnowledge Base, as well as by the miRTarBase
[56], miRecords [131], and TargetScan [73] databases. The Ingenuity RKnowledge
Base is based upon the collated ndings of patient phenotypes and disease, cellu-
lar, molecular, and sequence mechanisms, and all connections between miRNAs and
mRNAs are supported by at least one reference in the scientic literature. The Tar-
getScan database provided predicted regulatory mRNA/miRNA pairs, whereas both
miRTarBase and miRecords provided a mix of published, experimentally validated,
and predicted mRNA and miRNA pairings. In our analysis, only those binding re-
lationships considered to be highly conserved by TargetScan were considered to be
predicted targets in our analysis (Tables 5.45.5). IPA considers all relationships,
both highly and poorly conserved; therefore, additional predicated relationships were
found through the TargetScan database using IPA that were not identied through
our second derivative analysis. It is worth noting that vegfa was experimentally con-
rmed in the brosis analysis to be an experimentally conrmed target of the tumor
suppressor miRNA mir-205-5p [130] and the oncogenic miRNA mir-330-3p [135]. In
our previous study, vegfa was predicted to be involved in both MWCNT-induced
lung inammation and brosis using both in vivo and in vitro mRNA and protein
assays [37]. The interactions with these potential miRNA regulators could provide
new insights into post-transcriptional regulatory mechanisms involved in MWCNT-
induced lung angiogenesis, inammation, and brosis. In addition, mir-23b-3p was
experimentally conrmed as regulator of smad4 [99], and mir-34c-3p was identied
as a potential regulator of smad4 in MWCNT-induced brosis (Table 5.3), revealing
potential involvement of the tgf- signaling pathway.
The regulatory networks of mRNA and miRNA determined by both IPA analysis
and predicted binding due to sequence similarity in this study give a detailed view of
potential regulatory networks and signaling pathways involved in MWCNT-induced
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inammation and brosis. Core analysis of the signicant integrated inammatory
mRNA and miRNA detected pathways involved cytoskeletal remodeling, acute-phase
and stress responses, cell adhesion and growth, and the accumulation of ECM pro-
teins. Core analysis of the integrated brotic mRNA and miRNA (both NFM and
IPA) detected pathways involved in the accumulation of ECM protein, chronic in-
ammation, innate and acquired immunity, cellular transcription and metastasis,
integrin/ECM signaling, and leukocyte migration, suggesting that the miRNA and
mRNA regulatory networks determined by our analysis are reective of the inam-
matory response and tissue remodeling that takes place during MWCNT exposure
and the onset of brosis.
5.3 Publications
The work described in this chapter has been published in two journal manuscripts
both as joint rst author with Dr. Brandi Synder-Talkington.
J. Dymacek, B. N. Snyder-Talkington, D. W. Porter, M. G. Wolfarth, R. R.
Mercer, M. Pacurari, J. Denvir, V. Castranova, Y. Qian, and N. L. Guo. System based
identication of toxicity pathways associated with multi-walled carbon nanotube-
induced pathological responses. Toxicol Appl Pharmacol, 272(2):476 89, Oct 2013.
J. Dymacek, B. N. Snyder-Talkington, D. W. Porter, R. R. Mercer, M. G. Wol-
farth, V. Castranova, Y. Qian, and N. L. Guo. mrna and mirna regulatory networks
reective of multi-walled carbon nanotube-induced lung inammatory and brotic
pathologies in mice. Toxicol Sci, Dec 2014.
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Chapter 6
Summary and Future Work
6.1 Summary
This research focuses on developing algorithms to identify genes that are function-
ally related to our bodies' response to disease. As genomic medical research evolves,
we continue to explore whether genes can predict disease or prescribe a cure. By
identifying gene response to certain stimuli, it may be possible to develop a standard
method for early prognosis of a disease and personalized treatment. Potential appli-
cations include early detection of lung disease in factory workers, early detection of
lung cancer, or early prognosis of chemotherapy drug treatment.
This thesis outlines a computational system for nding novel hypotheses about
involvement of diseases, processes, and functions from a combination of pathologi-
cal data, gene annotations, miRNA/mRNA regulatory information, and time series
dose response microarray data. The use of matrix factorization, optimization, and
randomized algorithms allows the computational system to reduce calculations from
days to hours while still running on a standard laptop. This research is a small step
towards successful personalized medicine.
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Analyzing time series microarray data is a dicult task; however, temporal in-
formation is useful for discovering functional mechanisms and causal relationships.
My system utilizes a non-negative matrix factorization (NMF) algorithm for extract-
ing underlying basis patterns in the gene expression data. These patterns represent
underlying functions guiding gene response. The patterns are then related to prior
biological knowledge in the form of known annotated pathways and relationships
between genes. The NMF algorithm incorporates pathological data and discovers
related sets of genes which are signicantly correlated to the pathology.
This algorithm nds biologically relevant pathways and genes with and without
pathological information. It has been used on genome-wide expression proles of
mouse lungs following aspiration of well dispersed multi-walled carbon nanotubes
(MWCNT), and has detected MWCNT-induced lung inammation, lung brosis,
and related pathways. The identied signicant pathways and genes are supported
by evidence in the literature and by biological validation (both in vitro and in vivo).
MWCNT are an important class of engineered nano-materials with broad applica-
tions in many industries [91]. Concerns over potential MWCNT-induced toxicity have
emerged, particularly due to the structural similarity between asbestos and MWCNT
[31]. Previous studies have shown that MWCNT induce lung damage, including in-
ammatory granulomas and substantial interstitial lung brosis [83, 96]. Pulmonary
brosis has a poor clinical outcome [13, 40] and may be a potential precursor to lung
cancer [137]. However, there are no clinically applicable biomarkers for early detec-
tion and no eective treatment for pulmonary brosis due to its late diagnosis and
poorly understood molecular mechanisms for initiation [55, 127].
Recently, there is emerging interest in exploring miRNAs as potential therapeutic
targets and biomarkers for diagnosis and prognosis. Advantages of miRNA biomark-
ers include their presence in various bodily uids [18, 85] and greater stability in
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prepared tissue samples, including formalin xation, relative to mRNA [62]. The use
of miRNA markers in the selection of appropriate treatments has the possibility for
improving patient outcomes by determining the best application of existing drugs.
Additionally, identifying miRNA biomarkers may aid in the development of novel
treatments through the elucidation of new pathways [7, 61]. Our computational sys-
tem could aid in the process of identifying miRNA biomarkers and in practice has
helped identify several miRNA for further studies.
Results from this system were used as preliminary ndings in a successful NIH
R01 grant application. (\Systematic assessment of multi-walled carbon nanotubes in
pulmonary disease" 1R01ES021764-01 Guo (PI) NIEHS/NHLBI $1,665,000)
Articles
J. Dymacek and N. L. Guo. Systems approach to identifying relevant pathways from
phenotype information in dose-dependent time series microarray data. In Proceed-
ings of the 2011 IEEE International Conference on Bioinformatics and Biomedicine,
BIBM '11, pages 290293, Atlanta, GA, USA, 2011. IEEE Computer Society.
J. Dymacek and N. L. Guo. Integrated mirna and mrna analysis of time series
microarray data. In Proceedings of the 5th ACM Conference on Bioinformatics, Com-
putational Biology, and Health Informatics, BCB '14, pages 122127, Newport Beach,
CA, USA, 2014. ACM.
J. Dymacek, B. N. Snyder-Talkington, D. W. Porter, M. G. Wolfarth, R. R.
Mercer, M. Pacurari, J. Denvir, V. Castranova, Y. Qian, and N. L. Guo. System based
identication of toxicity pathways associated with multi-walled carbon nanotube-
induced pathological responses. Toxicol Appl Pharmacol, 272(2):476 89, Oct 2013.
J. Dymacek, B. N. Snyder-Talkington, D. W. Porter, R. R. Mercer, M. G. Wol-
farth, V. Castranova, Y. Qian, and N. L. Guo. mrna and mirna regulatory networks
reective of multi-walled carbon nanotube-induced lung inammatory and brotic
pathologies in mice. Toxicol Sci, Dec 2014.
94
Posters
Dymacek, Julian et al. Identifying Signi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6.2 Limitations
The MEGPath system is not suited for modeling experimental data from experiments
with less than three conditions. The system runs in O(nm3) time for n genes and m
conditions meaning it is not ideal for experiments with high numbers of conditions.
Also, unlike parametric systems, no information can be implied from unobserved ex-
perimental conditions. While the system suggests that two doses may behave the
same, it can make no claim about unobserved middle doses. The system also de-
pends on curated gene sets, which depending on granularity, may be too general.
The use of second derivatives in the miRNA analysis detects rudimentary regulatory
relationships but implies a linear relationship over time or doses.
6.3 Future Work
Time Series Data Across Experiments
My collaborators at the National Institute of Occupational Safety and Health have
recently completed a year long MWCNT lung exposure experiment. This current ex-
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periment is a logical successor to the 56 day experiment I have worked on. Combining
microarray data from both experiments will provide a new, longer term data set use-
ful for the community at large. Unfortunately, changes in microarray technology and
slight experimental dierences make a straight forward combination dicult.
Gold Standard Data Set
A new mock \gold" standard data set would be useful for future exploration and
comparison of similar systems. The new data set would need to have underlying
functions inuencing genes and underlying networks connecting genes. In addition
the networks would need to be described as gene sets.
Better miRNA Integration
miRNA are a regulatory mechanism of mRNA. An integrated analysis of miRNA
and the mRNA targets provides a deeper understanding of the biological mechanisms
of disease response. There is the potential to relate miRNA back to the mRNA
annotated gene sets.
Distributed Implementation
A distributed implementation of the MEGPath matrix factorization algorithm can
reduce computation time from hours to minutes. There are many opportunities for
exploring distributed computing, parallel algorithms, and cloud computing. Obtain-
ing the probability density functions are trivially parallel.
Alternate Distance Measures
Currently, the Frobenius norm is used for distance calculations and for updating
the probability density functions in the MEGPath system. Possible improvements
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include the potential for limited sampling to nd covariance. There is potential to
both increase accuracy and speed with direct tie-ins to a distributed implementation.
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